☰

cached image

Jeffrey L. Cummings, MD,University of Washington 1974 - Publications

Affiliations: 
Neurology University of California, Los Angeles, Los Angeles, CA 
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=17
Website:
http://www.uclahealth.org/body.cfm?id=479&action=detail&ref=7535
Tree Info Grants Similar researchers PubMed Report error

500/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Banks SJ, Yhang E, Tripodis Y, Su Y, Protas H, Adler CH, Balcer LJ, Bernick C, Mez JB, Palmisano J, Barr WB, Wethe JV, Dodick DW, Mcclean MD, Martin B, ... ... Cummings JL, et al. Clinical Outcomes and Tau Pathology in Retired Football Players: Associations With Diagnosed and Witnessed Sleep Apnea. Neurology. Clinical Practice. 14: e200263. PMID 38425491 DOI: 10.1212/CPJ.0000000000200263  0.534
2024 Garcia MJ, Leadley R, Ross J, Bozeat S, Redhead G, Hansson O, Iwatsubo T, Villain N, Cummings J. Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review. Journal of Alzheimer's Disease Reports. 8: 203-240. PMID 38405341 DOI: 10.3233/ADR-230045  0.336
2024 Cheng F, Wang F, Tang J, Zhou Y, Fu Z, Zhang P, Haines JL, Leverenz JB, Gan L, Hu J, Rosen-Zvi M, Pieper AA, Cummings J. Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease. Cell Reports. Medicine. 5: 101379. PMID 38382465 DOI: 10.1016/j.xcrm.2023.101379  0.319
2024 Reiman EM, Cummings JL, Langbaum JB, Mattke S, Alexander RC. A chance to prevent Alzheimer's disease sooner than you think. The Lancet. Neurology. 23: 144-145. PMID 38267187 DOI: 10.1016/S1474-4422(23)00508-2  0.306
2024 Lanctôt KL, Boada M, Tariot PN, Dabbous F, Hahn-Pedersen J, Udayachalerm S, Raket LL, Saiontz-Martinez C, Michalak W, Weidner W, Cummings J. Association between clinical dementia rating and clinical outcomes in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 16: e12522. PMID 38239329 DOI: 10.1002/dad2.12522  0.343
2023 Ly MT, Tuz-Zahra F, Tripodis Y, Adler CH, Balcer LJ, Bernick C, Zetterberg H, Blennow K, Peskind ER, Au R, Banks SJ, Barr WB, Wethe JV, Bondi MW, Delano-Wood LM, ... ... Cummings JL, et al. Association of Vascular Risk Factors and CSF and Imaging Biomarkers With White Matter Hyperintensities in Former American Football Players. Neurology. 102: e208030. PMID 38165330 DOI: 10.1212/WNL.0000000000208030  0.489
2023 Su Y, Protas H, Luo J, Chen K, Alosco ML, Adler CH, Balcer LJ, Bernick C, Au R, Banks SJ, Barr WB, Coleman MJ, Dodick DW, Katz DI, Marek KL, ... ... Cummings JL, et al. Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38134231 DOI: 10.1002/alz.13602  0.489
2023 Yang Z, Banks SJ, Ritter AR, Cummings JL, Sreenivasan K, Kinney JW, Caldwell JK, Wong CG, Miller JB, Cordes D. Microglial Imaging in Alzheimer's Disease and Its Relationship to Brain Amyloid: A Human 18F-GE180 PET Study. Journal of Alzheimer's Disease : Jad. PMID 37980664 DOI: 10.3233/JAD-230631  0.53
2023 Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 37955845 DOI: 10.1007/s40259-023-00633-2  0.33
2023 Yang Z, Sreenivasan K, Toledano Strom EN, Osse AML, Pasia LG, Cosme CG, Mugosa MRN, Chevalier EL, Ritter A, Miller JB, Cordes D, Cummings JL, Kinney JW. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease. Alzheimer's Research & Therapy. 15: 190. PMID 37924152 DOI: 10.1186/s13195-023-01340-4  0.325
2023 Dubois B, von Arnim CAF, Burnie N, Bozeat S, Cummings J. Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimer's Research & Therapy. 15: 175. PMID 37833762 DOI: 10.1186/s13195-023-01314-6  0.31
2023 Stern RA, Trujillo-Rodriguez D, Tripodis Y, Pulukuri SV, Alosco ML, Adler CH, Balcer LJ, Bernick C, Baucom Z, Marek KL, McClean MD, Johnson KA, McKee AC, Stein TD, Mez J, ... ... Cummings JL, et al. Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project. Alzheimer's Research & Therapy. 15: 166. PMID 37798671 DOI: 10.1186/s13195-023-01315-5  0.313
2023 Cummings J, Hahn-Pedersen JH, Eichinger CS, Freeman C, Clark A, Tarazona LRS, Lanctôt K. Exploring the relationship between patient-relevant outcomes and Alzheimer's disease progression assessed using the clinical dementia rating scale: a systematic literature review. Frontiers in Neurology. 14: 1208802. PMID 37669257 DOI: 10.3389/fneur.2023.1208802  0.329
2023 Goodwin GJ, Moeller S, Nguyen A, Cummings JL, John SE. Network analysis of neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's Research & Therapy. 15: 135. PMID 37568209 DOI: 10.1186/s13195-023-01279-6  0.314
2023 Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimer's & Dementia (New York, N. Y.). 9: e12385. PMID 37251912 DOI: 10.1002/trc2.12385  0.339
2023 Zhang P, Hou Y, Chiang CW, Pieper AA, Cummings J, Cheng F. Reply to: Comparator choices in pharmacoepidemiology studies of Alzheimer's disease. Nature Aging. PMID 37217662 DOI: 10.1038/s43587-023-00418-w  0.31
2023 Yang Z, Cummings JL, Kinney JW, Cordes D. Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients. Frontiers in Neuroscience. 17: 1151820. PMID 37123373 DOI: 10.3389/fnins.2023.1151820  0.33
2023 Voss T, Kost J, Mercer SP, Furtek C, Randolph C, Lines C, Egan MF, Cummings JL. Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions. Journal of Alzheimer's Disease : Jad. PMID 36744336 DOI: 10.3233/JAD-220836  0.362
2023 Alosco ML, Barr WB, Banks SJ, Wethe JV, Miller JB, Pulukuri SV, Culhane J, Tripodis Y, Adler CH, Balcer LJ, Bernick C, Mariani ML, Cantu RC, Dodick DW, McClean MD, ... ... Cummings JL, et al. Neuropsychological test performance of former American football players. Alzheimer's Research & Therapy. 15: 1. PMID 36597138 DOI: 10.1186/s13195-022-01147-9  0.488
2022 Alosco ML, Tripodis Y, Baucom ZH, Adler CH, Balcer LJ, Bernick C, Mariani ML, Au R, Banks SJ, Barr WB, Wethe JV, Cantu RC, Coleman MJ, Dodick DW, McClean MD, ... ... Cummings JL, et al. White matter hyperintensities in former American football players. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35996231 DOI: 10.1002/alz.12779  0.472
2022 Yang Z, Cieri F, Kinney JW, Cummings JL, Cordes D, Caldwell JZK. Brain functional topology differs by sex in cognitively normal older adults. Cerebral Cortex Communications. 3: tgac023. PMID 35795479 DOI: 10.1093/texcom/tgac023  0.315
2022 Nirogi R, Ieni J, Goyal VK, Ravula J, Jetta S, Shinde A, Jayarajan P, Benade V, Palacharla VRC, Dogiparti DK, Jasti V, Atri A, Cummings J. Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study. Alzheimer's & Dementia (New York, N. Y.). 8: e12307. PMID 35662833 DOI: 10.1002/trc2.12307  0.336
2022 Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2022. Alzheimer's & Dementia (New York, N. Y.). 8: e12295. PMID 35516416 DOI: 10.1002/trc2.12295  0.344
2022 Assunção SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, Atri A, Cummings J. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. Alzheimer's Research & Therapy. 14: 54. PMID 35440022 DOI: 10.1186/s13195-022-00984-y  0.356
2022 Holmgren S, Andersson T, Berglund A, Aarsland D, Cummings J, Freund-Levi Y. Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. The Journal of Neuropsychiatry and Clinical Neurosciences. appineuropsych210501. PMID 35306829 DOI: 10.1176/appi.neuropsych.21050135  0.34
2021 Fang J, Zhang P, Zhou Y, Chiang CW, Tan J, Hou Y, Stauffer S, Li L, Pieper AA, Cummings J, Cheng F. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease. Nature Aging. 1: 1175-1188. PMID 35572351 DOI: 10.1038/s43587-021-00138-z  0.328
2021 van Bokhoven P, de Wilde A, Vermunt L, Leferink PS, Heetveld S, Cummings J, Scheltens P, Vijverberg EGB. The Alzheimer's disease drug development landscape. Alzheimer's Research & Therapy. 13: 186. PMID 34763720 DOI: 10.1186/s13195-021-00927-z  0.332
2021 Potashman M, Buessing M, Levitchi Benea M, Cummings J, Borson S, Pemberton-Ross P, Epstein AJ. Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data. Neurology and Therapy. PMID 34431074 DOI: 10.1007/s40120-021-00272-1  0.303
2021 Alosco ML, Mariani ML, Adler CH, Balcer LJ, Bernick C, Au R, Banks SJ, Barr WB, Bouix S, Cantu RC, Coleman MJ, Dodick DW, Farrer LA, Geda YE, Katz DI, ... ... Cummings JL, et al. Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. Alzheimer's Research & Therapy. 13: 136. PMID 34384490 DOI: 10.1186/s13195-021-00872-x  0.502
2021 Cummings J, Bauzon J, Lee G. Who funds Alzheimer's disease drug development? Alzheimer's & Dementia (New York, N. Y.). 7: e12185. PMID 34095442 DOI: 10.1002/trc2.12185  0.3
2021 Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. Alzheimer's & Dementia (New York, N. Y.). 7: e12179. PMID 34095440 DOI: 10.1002/trc2.12179  0.308
2021 Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, ... Cummings JL, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. The Lancet. Neurology. PMID 33933186 DOI: 10.1016/S1474-4422(21)00066-1  0.348
2021 Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's Research & Therapy. 13: 80. PMID 33865446 DOI: 10.1186/s13195-021-00813-8  0.323
2021 Katz DI, Bernick C, Dodick DW, Mez J, Mariani ML, Adler CH, Alosco ML, Balcer LJ, Banks SJ, Barr WB, Brody DL, Cantu RC, Dams-O'Connor K, Geda YE, Jordan BD, ... ... Cummings JL, et al. National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology. PMID 33722990 DOI: 10.1212/WNL.0000000000011850  0.49
2021 Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet (London, England). PMID 33667416 DOI: 10.1016/S0140-6736(20)32205-4  0.347
2021 Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Molecular Neurodegeneration. 16: 2. PMID 33441154 DOI: 10.1186/s13024-021-00424-9  0.365
2020 Cummings J, Pinto LC, Cruz M, Fischer CE, Gerritsen DL, Grossberg GT, Hwang TJ, Ismail Z, Jeste DV, Koopmans R, Lanctot KL, Mateos R, Peschin S, Sampaio C, Tsuang D, et al. Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 32958332 DOI: 10.1016/J.Jagp.2020.09.002  0.304
2020 Ballard C, Aarsland D, Cummings J, O'Brien J, Mills R, Molinuevo JL, Fladby T, Williams G, Doherty P, Corbett A, Sultana J. Drug repositioning and repurposing for Alzheimer disease. Nature Reviews. Neurology. PMID 32939050 DOI: 10.1038/S41582-020-0397-4  0.405
2020 Cummings J. The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 32819825 DOI: 10.1016/J.Jagp.2020.07.011  0.436
2020 Bauzon J, Lee G, Cummings J. Repurposed agents in the Alzheimer's disease drug development pipeline. Alzheimer's Research & Therapy. 12: 98. PMID 32807237 DOI: 10.1186/S13195-020-00662-X  0.359
2020 Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimer's & Dementia (New York, N. Y.). 6: e12050. PMID 32695874 DOI: 10.1002/Trc2.12050  0.431
2020 Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB, Cummings J, Cheng F. Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. Medicinal Research Reviews. PMID 32656864 DOI: 10.1002/Med.21709  0.391
2020 Cummings JL. Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. Dementia and Geriatric Cognitive Disorders. 1-16. PMID 32512572 DOI: 10.1159/000507569  0.356
2020 Henderson ST, Morimoto BH, Cummings JL, Farlow MR, Walker J. A Placebo-Controlled, Parallel Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 32310169 DOI: 10.3233/Jad-191302  0.425
2019 Fischer CE, Ismail Z, Youakim JM, Creese B, Kumar S, Nuñez N, Darby RR, Di Vita A, D'Antonio F, de Lena C, McGeown WJ, Ramit R, Rasmussen J, Bell J, Wang H, ... Cummings J, et al. Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. Journal of Alzheimer's Disease : Jad. PMID 31884469 DOI: 10.3233/Jad-190828  0.457
2019 Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O. Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimer's Research & Therapy. 11: 109. PMID 31878968 DOI: 10.1186/S13195-019-0565-1  0.6
2019 Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade RD, Cummings JL. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 31708380 DOI: 10.1016/J.Jagp.2019.09.009  0.372
2019 Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opinion On Investigational Drugs. PMID 31614096 DOI: 10.1080/13543784.2019.1681398  0.365
2019 Caldwell JZK, Zhuang X, Leavitt MJ, Banks SJ, Cummings J, Cordes D. Sex Moderates Amyloid and Apolipoprotein ε4 Effects on Default Mode Network Connectivity at Rest. Frontiers in Neurology. 10: 900. PMID 31481928 DOI: 10.3389/Fneur.2019.00900  0.61
2019 Cummings J, Feldman HH, Scheltens P. The "rights" of precision drug development for Alzheimer's disease. Alzheimer's Research & Therapy. 11: 76. PMID 31470905 DOI: 10.1186/S13195-019-0529-5  0.354
2019 Cummings J, Passmore P, McGuinness B, Mok V, Chen C, Engelborghs S, Woodward M, Manzano S, Garcia-Ribas G, Cappa S, Bertolucci P, Chu LW. Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. Alzheimer's Research & Therapy. 11: 73. PMID 31421681 DOI: 10.1186/S13195-019-0528-6  0.327
2019 Brunet HE, Cummings JL, Banks SJ, Miller JB. Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults. Journal of Geriatric Psychiatry and Neurology. 891988719868311. PMID 31401920 DOI: 10.1177/0891988719868311  0.577
2019 Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Alzheimer's Research & Therapy. 11: 68. PMID 31387606 DOI: 10.1186/S13195-019-0520-1  0.357
2019 Bernard K, Gouttefangeas S, Bretin S, Galtier S, Robert P, Holthoff-Detto V, Cummings J, Pueyo M. A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. Alzheimer's & Dementia (New York, N. Y.). 5: 231-240. PMID 31297437 DOI: 10.1016/J.Trci.2019.04.002  0.395
2019 Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, Tariot PN, Raket LL. Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 164-174. PMID 31193334 DOI: 10.1016/J.Trci.2019.04.001  0.453
2019 Bayram E, Shan G, Cummings JL. Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 31127776 DOI: 10.3233/Jad-181285  0.438
2019 Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. The New England Journal of Medicine. 380: 1408-1420. PMID 30970186 DOI: 10.1056/Nejmoa1812840  0.433
2019 Cummings J. The Role of Biomarkers in Alzheimer's Disease Drug Development. Advances in Experimental Medicine and Biology. 1118: 29-61. PMID 30747416 DOI: 10.1007/978-3-030-05542-4_2  0.402
2019 Cummings JL, Tong G, Ballard C. Treatment Combinations for Alzheimer's Disease: Current And Future Pharmacotherapy Options. Journal of Alzheimer's Disease : Jad. PMID 30689575 DOI: 10.3233/Jad-180766  0.403
2019 Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Geist MA, Raket LL, Cummings JL. Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 67: 303-313. PMID 30636738 DOI: 10.3233/Jad-180595  0.353
2019 Abate G, Vezzoli M, Polito L, Guaita A, Memo M, Fowler C, Cummings JL, Uberti D. P4-551: Validation Of A New Antibody That Recognizes A Conformational Variant Of P53 Specific For Alzheimer'S At The Pre-Clinical And Prodromal Stages Of The Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.08.098  0.35
2019 Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, Tariot PN, Aisen PS, Vellas B, Voss T, Mukai Y, Michelson D, Egan MF. O3‐10‐02: Verubecestat‐Induced Brain Volume Loss Occurs Rapidly And Only In Amyloid‐Enriched Brain Regions In Epoch, A Phase 3 Trial In Mild‐To‐Moderate Alzheimer'S Disease Patients Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4679  0.341
2019 Egan MF, Kost J, Lines C, Voss T, Mozley LH, Furtek C, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, Dupre N, Randolph C, Sur C, Michelson D. Fts3-01-05: Further Analyses Of Cognitive Outcomes In The Apecs Phase-3 Trial Of Verubecestat In Prodromal Ad Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4622  0.346
2019 Chen J, Mize T, Wu X, Dutreil M, Moreno M, Wang X, Caberoy N, Samentar L, Nimgaonkar V, Cummings JL, Chen X. P3-204: Patient-Derived Microglia Cellular Model Towards Better Understanding Neuroimmunology Of Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3234  0.399
2019 Cummings JL, Johansson JO, Sweeney M, Kulikowski E, Wong NC, Halliday C, Lebioda K, Winblad B, Zetterberg H, Kalantar-Zadeh K, Nicholls SJ, Schwartz GG, Ray KK. P1-058: EFFECTS OF THE EPIGENETIC BET-INHIBITOR SMALL MOLECULE APABETALONE ON COGNITION IN PATIENTS WITH DIABETES AND CARDIOVASCULAR DISEASE Alzheimer's & Dementia. 15: P255-P255. DOI: 10.1016/J.Jalz.2019.06.083  0.307
2018 Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O'Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, et al. Current state of Alzheimer's fluid biomarkers. Acta Neuropathologica. 136: 821-853. PMID 30488277 DOI: 10.1007/S00401-018-1932-X  0.415
2018 Cummings JL, Atri A, Ballard C, Boneva N, Frölich L, Molinuevo JL, Raket LL, Tariot PN. Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. Alzheimer's Research & Therapy. 10: 116. PMID 30474567 DOI: 10.1186/S13195-018-0443-2  0.346
2018 Banks SJ, Zhuang X, Bayram E, Bird C, Cordes D, Caldwell JZK, Cummings JL. Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 30412488 DOI: 10.3233/Jad-180541  0.617
2018 Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S. Pimavanserin: Potential Treatment For Dementia-Related Psychosis. The Journal of Prevention of Alzheimer's Disease. 5: 253-258. PMID 30298184 DOI: 10.14283/jpad.2018.29  0.33
2018 Finger E, Berry S, Cummings J, Coleman K, Hsiung R, Feldman HH, Boxer A. Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). Alzheimer's Research & Therapy. 10: 102. PMID 30261917 DOI: 10.1186/S13195-018-0427-2  0.339
2018 Bluett B, Banks S, Cordes D, Bayram E, Mishra V, Cummings J, Litvan I. Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease. Alzheimer's & Dementia (New York, N. Y.). 4: 387-394. PMID 30211293 DOI: 10.1016/J.Trci.2018.04.010  0.576
2018 Cordes D, Zhuang X, Kaleem M, Sreenivasan K, Yang Z, Mishra V, Banks SJ, Bluett B, Cummings JL. Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson's disease. Alzheimer's & Dementia (New York, N. Y.). 4: 372-386. PMID 30175232 DOI: 10.1016/J.Trci.2018.04.009  0.552
2018 Shan G, Banks S, Miller JB, Ritter A, Bernick C, Lombardo J, Cummings JL. Statistical advances in clinical trials and clinical research. Alzheimer's & Dementia (New York, N. Y.). 4: 366-371. PMID 30175231 DOI: 10.1016/J.Trci.2018.04.006  0.555
2018 Miller JB, Cummings J, Nance C, Ritter A. Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. Alzheimer's & Dementia (New York, N. Y.). 4: 350-356. PMID 30175229 DOI: 10.1016/J.Trci.2018.06.006  0.412
2018 Cummings J, Reiber C, Kumar P. The price of progress: Funding and financing Alzheimer's disease drug development. Alzheimer's & Dementia (New York, N. Y.). 4: 330-343. PMID 30175227 DOI: 10.1016/J.Trci.2018.04.008  0.4
2018 Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, Ossinalde C, Silverman DH. Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. Experimental Gerontology. PMID 30006299 DOI: 10.1016/J.Exger.2018.07.009  0.412
2018 Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimer's & Dementia (New York, N. Y.). 4: 195-214. PMID 29955663 DOI: 10.1016/J.Trci.2019.05.008  0.417
2018 Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M, Michelson D. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 4: 173-181. PMID 29955661 DOI: 10.1016/J.Trci.2018.03.004  0.412
2018 Cummings J. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29936146 DOI: 10.1016/J.Jalz.2018.05.006  0.439
2018 Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ. Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. Journal of Alzheimer's Disease : Jad. PMID 29865063 DOI: 10.3233/Jad-180028  0.619
2018 Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. The New England Journal of Medicine. 378: 1691-1703. PMID 29719179 DOI: 10.1056/Nejmoa1706441  0.368
2018 Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. PMID 29695589 DOI: 10.1212/WNL.0000000000005550  0.308
2018 Cummings J, Ritter A, Zhong K. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. Journal of Alzheimer's Disease : Jad. PMID 29562511 DOI: 10.3233/Jad-179901  0.409
2018 Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, et al. Precision pharmacology for Alzheimer's disease. Pharmacological Research. PMID 29458203 DOI: 10.1016/J.Phrs.2018.02.014  0.363
2018 Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. The Lancet. Neurology. 17: 213-222. PMID 29452684 DOI: 10.1016/S1474-4422(18)30039-5  0.401
2018 Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB. Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study. Journal of Alzheimer's Disease : Jad. 62: 93-97. PMID 29439349 DOI: 10.3233/Jad-170896  0.323
2018 Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. Jama. 319: 130-142. PMID 29318278 DOI: 10.1001/Jama.2017.20373  0.459
2018 Brunet H, Cummings J, Banks S, Miller J. A - 26Awareness of Psychiatric Symptoms and Caregiver Distress Among Older Adults in a Memory Disorders Clinic Archives of Clinical Neuropsychology. 33: 703-794. DOI: 10.1093/arclin/acy061.26  0.489
2018 Matthews DC, Andrews RD, Lukic AS, Mishra VR, Banks SJ, Cummings JL, Bernick C, Initiative ADN. P1-380: Mri Classifiers Characterize Mild Traumatic Brain Injury In Symptomatic And Presymptomatic Stages And Differentiate From Alzheimer'S Disease-Related Impairment Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.388  0.6
2018 Egan MF, Voss T, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Dyck CHv, Sur C, Mukai Y, Furtek C, Mahoney EM, Mozley LH, Mo Y, Michelson D. P4-013: Design Of A Phase-3 Trial (Apecs) To Evaluate The Bace Inhibitor Verubecestat In Prodromal Ad Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2415  0.315
2018 Caldwell JZK, Pai A, Sørensen L, Kaylegian J, Cummings JL, Banks SJ. P2-426: Hippocampal Texture In Healthy Cognition And Mild Cognitive Impairment: The Impact Of Amyloid Burden And Sex Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1118  0.582
2017 Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, et al. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology. PMID 29237794 DOI: 10.1212/Wnl.0000000000004798  0.305
2017 Cummings J, Fox N. Defining Disease Modifying Therapy for Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 4: 109-115. PMID 29071250 DOI: 10.14283/jpad.2017.12  0.311
2017 Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2017. Alzheimer's & Dementia (New York, N. Y.). 3: 367-384. PMID 29067343 DOI: 10.1016/J.Trci.2017.05.002  0.407
2017 Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Riordan H, Scheinin M, Soininen H, Rouru J. Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 3: 1-9. PMID 29067315 DOI: 10.1016/J.Trci.2016.11.004  0.407
2017 Cummings J. Disease modification and Neuroprotection in neurodegenerative disorders. Translational Neurodegeneration. 6: 25. PMID 29021896 DOI: 10.1186/S40035-017-0096-2  0.401
2017 Caldwell JZK, Berg JL, Cummings JL, Banks SJ. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. Alzheimer's Research & Therapy. 9: 72. PMID 28899422 DOI: 10.1186/S13195-017-0300-8  0.606
2017 Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research & Therapy. 9: 60. PMID 28793924 DOI: 10.1186/S13195-017-0283-5  0.44
2017 Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clinical and Translational Science. PMID 28767185 DOI: 10.1111/Cts.12491  0.328
2017 Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B, Freund-Levi Y. Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. Journal of Alzheimer's Disease : Jad. PMID 28269767 DOI: 10.3233/Jad-160758  0.441
2017 Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanctôt KL, Miller DS, Mortby ME, Onyike CU, Rosenberg PB, et al. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. Journal of Alzheimer's Disease : Jad. PMID 28059789 DOI: 10.3233/Jad-160979  0.402
2017 Atri A, Cummings JL, Hendrix S, Ellison N, Andersen KA, Edwards J. MAINTENANCE OF COGNITIVE IMPROVEMENT TREATMENT RESPONSE WITH MEMANTINE AND DONEPEZIL: POST HOC ANALYSES FROM A PLACEBO-CONTROLLED STUDY IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE Alzheimer's & Dementia. 13: P1232. DOI: 10.1016/J.Jalz.2017.07.430  0.371
2017 Cummings JL, Bernard K, Bretin S, Gouttefangeas S, Pueyo M. PHASE II CLINICAL TRIAL WITH AN AMPA-POSITIVE ALLOSTERIC MODULATOR (S 47445): BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS SUFFERING FROM ALZHEIMER’S DISEASE AT MILD TO MODERATE STAGES WITH DEPRESSIVE SYMPTOMS Alzheimer's & Dementia. 13: P575. DOI: 10.1016/J.Jalz.2017.07.195  0.331
2017 Bloniecki V, Freund-Levi Y, Blennow K, Aarsland D, Cummings JL, Winblad B. Effects Of Risperidone And Galantamine Treatment On Alzheimer Biomarker Levels In Cerebrospinal Fluid Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.1487  0.309
2016 Cummings J, Morstorf T, Lee G. Alzheimer's drug-development pipeline: 2016. Alzheimer's & Dementia (New York, N. Y.). 2: 222-232. PMID 29067309 DOI: 10.1016/J.Trci.2016.07.001  0.409
2016 Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research & Therapy. 8: 39. PMID 27646601 DOI: 10.1186/S13195-016-0207-9  0.414
2016 Cummings JL, Siffert J. Erratum: Dextromethorphan-quinidine for agitation in Alzheimer disease [letter reply] (JAMA (2016) 315:11 (1166-1167)) Jama. 315. PMID 27092842 DOI: 10.1001/Jama.2016.3949  0.421
2016 Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, ... ... Cummings J, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/J.Jalz.2016.02.002  0.403
2016 Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 27010616 DOI: 10.1136/Jnnp-2015-312383  0.445
2016 Cummings JL, Siffert J. Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply. Jama. 315: 1166-7. PMID 26978215 DOI: 10.1001/Jama.2015.18289  0.423
2016 Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. Alzheimer's Research & Therapy. 8: 4. PMID 26822146 DOI: 10.1186/S13195-016-0173-2  0.42
2016 Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, Dash A. Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. Cns Neuroscience & Therapeutics. PMID 26778658 DOI: 10.1111/Cns.12484  0.432
2016 Tolar M, Vellas B, Cummings J, Porsteinsson A, Abushakra S, Hey J. Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate ad: combined sub-group analyses from two Phase 3 trials Neurobiology of Aging. 39. DOI: 10.1016/J.Neurobiolaging.2016.01.100  0.333
2016 Abushakra S, Vellas B, Cummings J, Hey J, Tolar M, Power A. Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous ad patients: efficacy and safety analyses from two Phase 3 trials Neurobiology of Aging. 39. DOI: 10.1016/J.Neurobiolaging.2016.01.099  0.34
2016 Ritchie CW, Webster S, Cummings JL, Masters CL, Ruffles V, Seckl J, Walker BR. P4-388: XANAMEMTM : A Novel 11B-HSD1 Inhibitor with Potential to Provide Durable Symptomatic and Disease Modifying Benefits in Alzheimer’S Disease Alzheimer's & Dementia. 12: P1186-P1186. DOI: 10.1016/J.Jalz.2016.07.133  0.326
2016 Ismail Z, Brodaty H, Cieslak A, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanctot KL, Miller D, Mortby ME, Onyike C, Ortiz LA, Rosenberg P, Smith EE, ... ... Cummings JL, et al. The Mild Behavioral Impairment Checklist (Mbi-C): A New Rating Scale For Neuropsychiatric Symptoms As Early Manifestations Of Neurodegenerative Disease Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.366  0.333
2015 Vogel SJ, Banks SJ, Cummings JL, Miller JB. Concordance of the Montreal cognitive assessment with standard neuropsychological measures. Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 289-94. PMID 27239512 DOI: 10.1016/J.Dadm.2015.05.002  0.555
2015 Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. Nature Reviews. Disease Primers. 1: 15056. PMID 27188934 DOI: 10.1038/nrdp.2015.56  0.311
2015 Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). The Journal of Prevention of Alzheimer's Disease. 2: 227-241. PMID 27019841 DOI: 10.14283/jpad.2015.82  0.321
2015 Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, ... ... Cummings JL, et al. Erratum: Early behavioural changes in familial Alzheimers disease in the Dominantly Inherited Alzheimer Network (Brain (2015) 138 (103645) (10.1093/brain/awv004)) Brain. 138. PMID 26598496 DOI: 10.1093/Brain/Awv210  0.347
2015 Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research. 12: 712-22. PMID 26412218 DOI: 10.2174/1567205012666150701103107  0.456
2015 Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 47: 205-14. PMID 26402769 DOI: 10.3233/Jad-142508  0.425
2015 Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. Jama. 314: 1242-54. PMID 26393847 DOI: 10.1001/Jama.2015.10214  0.447
2015 Ritter A, Cummings J. Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Frontiers in Neurology. 6: 186. PMID 26379620 DOI: 10.3389/Fneur.2015.00186  0.396
2015 Cummings J, Zhong K. Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. Clinical Pharmacology and Therapeutics. 98: 483-5. PMID 26206713 DOI: 10.1002/Cpt.190  0.438
2015 Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimer's Research & Therapy. 7: 43. PMID 26120369 DOI: 10.1186/S13195-015-0127-0  0.451
2015 Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimer's Research & Therapy. 7: 39. PMID 26120368 DOI: 10.1186/S13195-015-0122-5  0.369
2015 Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q, Tang M, Wu J, Xu Q, Li H, Cummings JL. Incidence of dementia and subtypes: A cohort study in four regions in China. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26086181 DOI: 10.1016/J.Jalz.2015.02.011  0.33
2015 Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ. Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia. Journal of the American Geriatrics Society. 63: 1448-52. PMID 26046666 DOI: 10.1111/Jgs.13473  0.346
2015 Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer's disease: what, when, and why? Annals of Clinical and Translational Neurology. 2: 307-23. PMID 25815358 DOI: 10.1002/Acn3.166  0.456
2015 Cummings J, Friedman JH, Garibaldi G, Jones M, Macfadden W, Marsh L, Robert PH. Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials. Journal of Geriatric Psychiatry and Neurology. PMID 25809634 DOI: 10.1177/0891988715573534  0.387
2015 Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T, Strohmaier C. Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. Alzheimer's Research & Therapy. 7: 9. PMID 25755685 DOI: 10.1186/S13195-014-0088-8  0.307
2015 Petersen RB, Lissemore FM, Appleby B, Aggarwal N, Boyatzis R, Casadesus G, Cummings J, Jack A, Perry G, Safar J, Sajatovic M, Surewicz W, Wang Y, Whitehouse P, Lerner A. From Neurodegeneration to Brain Health: An Integrated Approach. Journal of Alzheimer's Disease : Jad. PMID 25720413 DOI: 10.3233/Jad-150043  0.308
2015 Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, ... ... Cummings JL, et al. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain : a Journal of Neurology. 138: 1036-45. PMID 25688083 DOI: 10.1093/Brain/Awv004  0.398
2015 Alva G, Cummings JL, Galvin JE, Meng X, Velting DM. Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. International Journal of Clinical Practice. 69: 518-30. PMID 25684069 DOI: 10.1111/Ijcp.12621  0.351
2015 Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG, Peskind E, Porsteinsson AP, Reich E, Sampaio C, Steffens D, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. International Psychogeriatrics / Ipa. 27: 7-17. PMID 25311499 DOI: 10.1017/S1041610214001963  0.329
2015 Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. Journal of Alzheimer's Disease : Jad. 43: 949-55. PMID 25125457 DOI: 10.3233/Jad-140792  0.425
2015 Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, Broich K, Cummings J, Dening K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, et al. Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 455-61. PMID 24751826 DOI: 10.1016/J.Jalz.2014.01.007  0.326
2015 Cummings JL, Lyketsos C, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gándara JE, Agronin M, Nguyen U, Shin P, Tariot PN, Siffert J. O4-09-05: Dextromethorphan/quinidine (AVP-923) for treatment of agitation in patients with Alzheimer's disease: Analysis of week 10 results for patients treated only with AVP-923 versus patients receiving only placebo (NCT01584440) Alzheimer's & Dementia. 11: P291-P292. DOI: 10.1016/J.Jalz.2015.07.397  0.35
2015 Goukasian N, LeClair H, Hwang KS, Ringman JM, Cummings JL, Apostolova LG. P4-047: Behavioral correlates of cognitive decline in normal aging and prodromal Alzheimer's disease Alzheimer's & Dementia. 11: P784-P784. DOI: 10.1016/J.Jalz.2015.06.1751  0.412
2015 Cummings JL, Lyketsos C, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gándara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J. P3-301: Dextromethorphan/quinidine (AVP-923) phase 2 study for treatment of agitation in Alzheimer's disease: Comparing the enrolled agitation sample with the international psychogeriatric association definition of agitation in cognitive disorders (NCT015 Alzheimer's & Dementia. 11: P751-P751. DOI: 10.1016/J.Jalz.2015.06.1675  0.401
2015 Goukasian N, LeClair H, Porat S, Hwang KS, Ringman JM, Silverman D, Cummings JL, Apostolova LG. Anxiety is associated with brain amyloidosis in cognitively normal and mild cognitive impairment subjects: A [18F]flutemetamol PET study Alzheimers & Dementia. 11: 17. DOI: 10.1016/J.Jalz.2015.06.028  0.424
2015 Cummings J, Lyketsos CG, Tariot P, Peskind E, Nguyen U, Knowles N, Shin P, Siffert J. Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440) The American Journal of Geriatric Psychiatry. 23: S164-S165. DOI: 10.1016/J.Jagp.2014.12.171  0.351
2015 Vogel SJ, Banks SJ, Cummings JL, Miller JB. Concordance of the Montreal cognitive assessment with standard neuropsychological measures Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 1: 289-294. DOI: 10.1016/j.dadm.2015.05.002  0.501
2014 Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, et al. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. The Journal of Prevention of Alzheimer's Disease. 1: 181-202. PMID 26478889 DOI: 10.14283/jpad.2014.32  0.328
2014 Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, Cummings J. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dementia and Geriatric Cognitive Disorders Extra. 4: 509-16. PMID 25685141 DOI: 10.1159/000357775  0.62
2014 Shen JH, Shen Q, Yu H, Lai JS, Beaumont JL, Zhang Z, Wang H, Kim SY, Chen C, Kwok T, Wang SJ, Lee DY, Harrison J, Cummings J. Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. American Journal of Neurodegenerative Disease. 3: 158-69. PMID 25628967  0.332
2014 Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, et al. Overcoming obstacles to repurposing for neurodegenerative disease. Annals of Clinical and Translational Neurology. 1: 512-8. PMID 25356422 DOI: 10.1002/Acn3.76  0.307
2014 Bloniecki V, Aarsland D, Cummings J, Blennow K, Freund-Levi Y. Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. Dementia and Geriatric Cognitive Disorders Extra. 4: 335-43. PMID 25298777 DOI: 10.1159/000363500  0.322
2014 Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Research & Therapy. 6: 37. PMID 25024750 DOI: 10.1186/Alzrt269  0.397
2014 Cummings JL, Tribanek M, Hoerr R. Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment. International Psychogeriatrics / Ipa. 26: 1871-4. PMID 24990088 DOI: 10.1017/S1041610214001185  0.332
2014 Miller JB, Banks SJ, Léger GC, Cummings JL. Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. Translational Neurodegeneration. 3: 12. PMID 24921043 DOI: 10.1186/2047-9158-3-12  0.599
2014 Pillai JA, Bonner-Jackson A, Walker E, Mourany L, Cummings JL. Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 38: 224-33. PMID 24903099 DOI: 10.1159/000362715  0.461
2014 Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, ... Cummings JL, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology. 13: 614-29. PMID 24849862 DOI: 10.1016/S1474-4422(14)70090-0  0.446
2014 Cummings JL, Ringman J, Vinters HV. Neuropathologic correlates of trial-related instruments for Alzheimer's disease. American Journal of Neurodegenerative Disease. 3: 45-9. PMID 24754002  0.329
2014 McLaughlin PM, Wright MJ, Larocca M, Nguyen PT, Teng E, Apostolova LG, Ringman JM, Zhou Y, Cummings JL, Woo E. The "Alzheimer's type" profile of semantic clustering in amnestic mild cognitive impairment. Journal of the International Neuropsychological Society : Jins. 20: 402-12. PMID 24521694 DOI: 10.1017/S135561771400006X  0.392
2014 Apostolova LG, Di LJ, Duffy EL, Brook J, Elashoff D, Tseng CH, Fairbanks L, Cummings JL. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 37: 315-26. PMID 24481207 DOI: 10.1159/000351009  0.451
2014 Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet (London, England). 383: 533-40. PMID 24183563 DOI: 10.1016/S0140-6736(13)62106-6  0.371
2014 Cummings J, Zhong K, Bernick C. The cleveland clinic lou ruvo center for brain health: Keeping memory alive Journal of Alzheimer's Disease. 38: 103-109. PMID 23948939 DOI: 10.3233/Jad-130791  0.34
2014 Cummings J, Zhong K. Biomarker-driven therapeutic management of alzheimer's disease: Establishing the foundations Clinical Pharmacology and Therapeutics. 95: 67-77. DOI: 10.1038/Clpt.2013.205  0.425
2014 Ballard C, Mills R, Williams H, Corbett A, Cummings J. Treatment of Psychosis in Parkinson's disease and Parkinson's disease dementia Neurobiology of Aging. 35. DOI: 10.1016/J.Neurobiolaging.2014.01.035  0.394
2014 Molinuevo JL, Cummings J, Frolich L, Galvin JE, Krahnke T, Strohmaier C. Up-Titration To High-Dose 13.3 Mg/24 H Rivastigmine Transdermal Patch May Provide Greater Benefit To Alzheimer'S Disease Patients Compared To Concomitant Use Of 9.5 Mg/24 H Patch And Memantine: Results From The Optima Study Alzheimers & Dementia. 10. DOI: 10.1016/J.Jalz.2014.05.1702  0.312
2014 Grill JD, Raman R, Ernstrom K, Dowsett S, Hake A, Aisen P, Doody R, Cummings J. P4-174: COMPARING RECRUITMENT AMONG GEOGRAPHIC REGIONS IN MULTINATIONAL ALZHEIMER'S DISEASE CLINICAL TRIALS Alzheimer's & Dementia. 10: P852-P853. DOI: 10.1016/J.Jalz.2014.05.1691  0.396
2014 Henley DB, Dowsett SA, Chen Y, Liu-Seifert H, Grill JD, Doody R, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. P4-101: REGIONAL VARIATION IN ALZHEIMER'S DISEASE PROGRESSION IN A CLINICAL TRIAL SETTING Alzheimer's & Dementia. 10: P821-P821. DOI: 10.1016/J.Jalz.2014.05.1617  0.393
2014 Liu-Seifert H, Han B, Henley D, Siemers E, Cummings J, Raskin J, Price K, Sundell K, Selzler K, Aisen P, Mohs R. Cognition Impairment Precedes And Predicts Functional Impairment In Mild Alzhiemer’S Disease Alzheimers & Dementia. 10: 203. DOI: 10.1016/J.Jalz.2014.05.1070  0.345
2014 Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, Clayton D, Mortensen D, Ho C, Paul R. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate The Efficacy And Safety Of Crenezumab In Patients With Mild To Moderate Alzheimer'S Disease Alzheimers & Dementia. 10: 275. DOI: 10.1016/J.Jalz.2014.04.450  0.355
2013 Appleby BS, Cummings JL. Discovering new treatments for Alzheimer's disease by repurposing approved medications. Current Topics in Medicinal Chemistry. 13: 2306-27. PMID 24059463 DOI: 10.2174/15680266113136660162  0.415
2013 Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C. Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease American Journal of Alzheimers Disease and Other Dementias. 28: 583-591. PMID 23982674 DOI: 10.1177/1533317513495104  0.377
2013 Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. Bmc Geriatrics. 13: 56. PMID 23742728 DOI: 10.1186/1471-2318-13-56  0.377
2013 Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. The Medical Clinics of North America. 97: 439-57. PMID 23642580 DOI: 10.1016/J.Mcna.2013.01.002  0.418
2013 Cummings JL, Dubois B, Molinuevo JL, Scheltens P. International Work Group criteria for the diagnosis of Alzheimer disease. The Medical Clinics of North America. 97: 363-8. PMID 23642575 DOI: 10.1016/J.Mcna.2013.01.001  0.425
2013 Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer's disease biomarkers: correspondence between human studies and animal models. Neurobiology of Disease. 56: 116-30. PMID 23631871 DOI: 10.1016/J.Nbd.2013.04.010  0.389
2013 Trzepacz PT, Saykin A, Yu P, Bhamditipati P, Sun J, Dennehy EB, Willis B, Cummings JL. Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 21: 607-22. PMID 23602309 DOI: 10.1016/J.Jagp.2012.10.027  0.453
2013 Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K. Alzheimer's disease drug development: translational neuroscience strategies. Cns Spectrums. 18: 128-38. PMID 23472637 DOI: 10.1017/S1092852913000023  0.605
2013 Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. Cns Neuroscience & Therapeutics. 19: 294-301. PMID 23462265 DOI: 10.1111/Cns.12076  0.396
2013 Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Liu L, Mackell J, Fain R. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research & Therapy. 5: 12. PMID 23433097 DOI: 10.1186/Alzrt166  0.338
2013 Kim HJ, Kang SJ, Kim C, Kim GH, Jeon S, Lee JM, Oh SJ, Kim JS, Choe YS, Lee KH, Noh Y, Cho H, Yoon CW, Chin J, Cummings JL, et al. The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiology of Aging. 34: 1913-20. PMID 23414669 DOI: 10.1016/J.Neurobiolaging.2013.01.002  0.396
2013 Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer's disease discovered in repurposed agents. Dementia and Geriatric Cognitive Disorders. 35: 1-22. PMID 23307039 DOI: 10.1159/000345791  0.416
2013 Senanarong V, Harnphadungkit K, Poungvarin N, Vannasaeng S, Chongwisal S, Chakorn T, Jamjumrus P, Raksthaput A, Chaichanettee S, Aoonkaew N, Udompunthurak S, Doody RS, Cummings JL. The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. Bmc Neurology. 13: 3. PMID 23305293 DOI: 10.1186/1471-2377-13-3  0.347
2013 Trzepacz PT, Cummings J, Konechnik T, Forrester TD, Chang C, Dennehy EB, Willis BA, Shuler C, Tabas LB, Lyketsos CG. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease International Psychogeriatrics. 25: 707-719. PMID 23257314 DOI: 10.1017/S1041610212002141  0.421
2013 Voss T, Bahr D, Cummings JL, Mills R, Ravina B, Williams H. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism & Related Disorders. 19: 295-299. PMID 23211417 DOI: 10.1016/J.Parkreldis.2012.10.022  0.357
2013 Cummings JL, Ihl R, Herrschaft H, Hoerr R, Tribanek M. Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. International Psychogeriatrics / Ipa. 25: 431-8. PMID 23194852 DOI: 10.1017/S1041610212001974  0.309
2013 Dubois B, Gauthier S, Cummings J. The utility of the new research diagnostic criteria for Alzheimer's disease. International Psychogeriatrics / Ipa. 25: 175-7. PMID 23148941 DOI: 10.1017/S1041610212002098  0.448
2013 Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, ... ... Cummings JL, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 189-98. PMID 23062850 DOI: 10.1016/J.Jalz.2012.03.003  0.39
2013 Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, ... ... Cummings J, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 176-88. PMID 23043900 DOI: 10.1016/J.Jalz.2012.03.002  0.381
2013 Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Thompson PM, Cummings JL, Bookheimer SY, Ringman JM. Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease. Human Brain Mapping. 34: 3308-19. PMID 22806961 DOI: 10.1002/Hbm.22141  0.637
2013 Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiology of Aging. 34: 62-72. PMID 22503160 DOI: 10.1016/J.Neurobiolaging.2012.03.006  0.435
2013 Sabbagh JJ, Kinney JW, Cummings JL. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiology of Aging. 34: 169-83. PMID 22464953 DOI: 10.1016/J.Neurobiolaging.2012.02.027  0.397
2013 Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Dhall R, Ballard C. Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020) Journal of the Neurological Sciences. 333. DOI: 10.1016/J.Jns.2013.07.401  0.313
2013 Molinuevo JL, Cummings J, Frölich L, Galvin J, Krahnke T, Strohmaier C. High-dose 13.3 mg/24 h rivastigmine patch efficacy and safety in mild-to-moderate Alzheimer's disease with and without concomitant memantine use Journal of the Neurological Sciences. 333. DOI: 10.1016/J.Jns.2013.07.1280  0.329
2013 Langbaum J, High N, Aisen P, Albert M, Brown K, Comer M, Cummings J, Manly J, Petersen R, Sperling R, Strobel G, Weiner M, Tariot P, Reiman E. Development and implementation of the National Alzheimer's Prevention Registry Alzheimers & Dementia. 9: 280. DOI: 10.1016/J.Jalz.2013.05.560  0.351
2013 Schoenfeld S, Tariot P, Peskind E, Cummings J, Lyketsos C, Nguyen U, Knowles N, Siffert J. Treatment of agitation in people with Alzheimer's dementia: Rationale for the clinical investigation of AVP-923 (dextromethorphan/quinidine) Alzheimers & Dementia. 9: 757. DOI: 10.1016/J.Jalz.2013.05.1534  0.369
2013 Cummings J, Bellelli G, Black S, Bakchine S, Krahnke T, Strohmaier C. The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study Alzheimers & Dementia. 9: 658. DOI: 10.1016/J.Jalz.2013.05.1352  0.4
2013 Ballard C, Mills R, Williams H, Chi-Burris K, Bahr D, Cummings J. O4-05-04: Antipsychotic efficacy and good tolerability in a Phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020) Alzheimer's & Dementia. 9: P690-P690. DOI: 10.1016/J.Jalz.2013.04.361  0.315
2013 Arias J, Ford P, Sharp RR, Rae-Grant A, Cummings J. O3-12-02: Perspectives on the benefits and harms of preclinical testing for Alzheimer's disease Alzheimer's & Dementia. 9: P546-P546. DOI: 10.1016/J.Jalz.2013.04.304  0.356
2012 Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, ... ... Cummings JL, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer's Research & Therapy. 4: 43. PMID 23107780 DOI: 10.1186/Alzrt146  0.41
2012 Cummings J. Alzheimer's disease diagnostic criteria: practical applications. Alzheimer's Research & Therapy. 4: 35. PMID 22947665 DOI: 10.1186/alzrt138  0.309
2012 Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 27: 421-32. PMID 22930699 DOI: 10.1177/1533317512454708  0.329
2012 Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 33: 341-53. PMID 22796905 DOI: 10.1159/000340056  0.354
2012 Cummings JL. Food for Thought: Souvenaid® in Mild Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 22776968 DOI: 10.3233/Jad-2012-121297  0.365
2012 Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Archives of Neurology. 69: 757-64. PMID 22689192 DOI: 10.1001/Archneurol.2012.277  0.311
2012 Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G. Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations. Dementia and Geriatric Cognitive Disorders. 33: 219-25. PMID 22584618 DOI: 10.1159/000338546  0.324
2012 Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Archives of Neurology. 69: 901-5. PMID 22431834 DOI: 10.1001/Archneurol.2011.3758  0.431
2012 Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a006395. PMID 22393531 DOI: 10.1101/Cshperspect.A006395  0.426
2012 Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 33: 1-5. PMID 22343824 DOI: 10.1159/000335729  0.662
2012 Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Archives of Neurology. 69: 96-104. PMID 22232349 DOI: 10.1001/Archneurol.2011.642  0.322
2012 Doody RS, Cummings JL, Farlow MR. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Current Alzheimer Research. 9: 773-81. PMID 22175653 DOI: 10.2174/156720512802455412  0.451
2012 Walker Z, Cummings JL. [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 74-83. PMID 22024052 DOI: 10.1016/J.Jalz.2011.08.003  0.369
2012 Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer SY, Ringman JM. Increased fMRI signal with age in familial Alzheimer's disease mutation carriers. Neurobiology of Aging. 33: 424.e11-21. PMID 21129823 DOI: 10.1016/J.Neurobiolaging.2010.09.028  0.655
2012 Andrawis JP, Hwang KS, Green AE, Kotlerman J, Elashoff D, Morra JH, Cummings JL, Toga AW, Thompson PM, Apostolova LG. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiology of Aging. 33: 856-66. PMID 20833446 DOI: 10.1016/J.Neurobiolaging.2010.07.020  0.435
2012 Cummings J, Hendrix S, Miller M, Pejovic V, Graham S, Tocco M. Extended-Release Memantine (28 mg, Once Daily) and Sustained Behavioral Improvement: Post Hoc Responder Analysis from a Randomized Trial in Patients with Moderate to Severe Alzheimer's Disease (P04.197) Neurology. 78: P04.197-P04.197. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.197  0.362
2012 Cummings J, Frolich L, Black S, Bakchine S, Bellelli G, Molinuevo J, Kressig R, Downs P, Caputo A, Strohmaier C. Managing Functional and Cognitive Decline in Patients with Mild-to-Moderate Alzheimer's Disease: A 48-Week, Randomized, Double-Blind Evaluation of 13.3 mg/24 h (15 cm{superscript 2}) Versus 9.5 mg/24 h (10 cm{superscript 2}) Rivastigmine Patch (P04.193) Neurology. 78: P04.193-P04.193. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.193  0.348
2012 Apostolova L, Di LJ, Tseng C, Fairbanks L, Elashoff D, Cummings J. Behavioral reserve in mild cognitive impairment and mild Alzheimer's disease Alzheimers & Dementia. 8: 323. DOI: 10.1016/J.Jalz.2012.05.893  0.417
2012 Dilley M, Mason K, Silverman D, Quach J, Beigi M, Ringman J, Cummings J, Grill J. P1-171: Ketogenic medical food consumption in Alzheimer's disease enhances the acute cerebral blood flow response in specific frontocortical and basal ganglia regions Alzheimer's & Dementia. 8: P168-P168. DOI: 10.1016/J.Jalz.2012.05.449  0.312
2012 Doody R, Winblad B, Cummings J, Tariot P, Sano M, Aisen P, Selby B, Seely L. Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials Alzheimers & Dementia. 8: 456. DOI: 10.1016/J.Jalz.2012.05.1217  0.4
2011 Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Gilbert PE, Liang LJ, Cummings JL, Ringman JM. Propositional density and apolipoprotein E genotype among persons at risk for familial Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 32: 188-92. PMID 22134129 DOI: 10.1159/000333023  0.625
2011 Cummings JL. Alzheimer's disease clinical trials: changing the paradigm. Current Psychiatry Reports. 13: 437-42. PMID 22052382 DOI: 10.1007/S11920-011-0234-Y  0.395
2011 Jones R, Wilkinson D, Lopez OL, Cummings J, Waldemar G, Zhang R, Mackell J, Gauthier S. Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease. Trials. 12: 233. PMID 22029822 DOI: 10.1186/1745-6215-12-233  0.302
2011 Apostolova LG, Hwang KS, Medina LD, Green AE, Braskie MN, Dutton RA, Lai J, Geschwind DH, Cummings JL, Thompson PM, Ringman JM. Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 32: 118-25. PMID 21952501 DOI: 10.1159/000330471  0.656
2011 Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR, Weiner MW, Thomas RG, Schneider LS, Tariot PN. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 77: 1263-71. PMID 21917762 DOI: 10.1212/Wnl.0B013E318230A16C  0.421
2011 Cummings J, Reynders R, Zhong K. Globalization of Alzheimer's disease clinical trials. Alzheimer's Research & Therapy. 3: 24. PMID 21861855 DOI: 10.1186/Alzrt86  0.348
2011 Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain : a Journal of Neurology. 134: 3146-66. PMID 21810889 DOI: 10.1093/Brain/Awr177  0.399
2011 Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry. 68: 853-61. PMID 21810649 DOI: 10.1001/Archgenpsychiatry.2011.72  0.412
2011 Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: e13-44. PMID 21550318 DOI: 10.1016/J.Jalz.2010.06.004  0.389
2011 Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. Bmc Neurology. 11: 21. PMID 21299848 DOI: 10.1186/1471-2377-11-21  0.438
2011 Ringman JM, Medina LD, Braskie M, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer S. Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task. Cerebral Cortex (New York, N.Y. : 1991). 21: 877-83. PMID 20729396 DOI: 10.1093/Cercor/Bhq158  0.645
2011 Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. International Journal of Geriatric Psychiatry. 26: 150-7. PMID 20597141 DOI: 10.1002/Gps.2507  0.429
2011 Hwang K, Gylys K, Taylor K, Thompson P, Cole G, Cummings J, Apostolova L. P2-037: Plasma BDNF associations with cortical thickness in normal controls and mild cognitive impairment Alzheimer's & Dementia. 7: S319-S319. DOI: 10.1016/J.Jalz.2011.05.927  0.304
2011 Apostolova LG, Klein E, Cummings J, Thompson P, Hwang K, Kohannim O, Coppola G, Gao F. Automated diagnostic classifiers for cognitively normal and mild cognitive impairment subjects using imaging, genotyping, and gene expression Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.337  0.302
2011 Shen J, Shen Q, Yu H, Zhang Z, Wang H, Kim SY, Kwok T, Chen C, Wang S, Lee DY, Cummings J, Harrison J, Lai J, Beaumont J, Cella D, et al. Alzheimer's disease instruments validation study in Asia Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.2193  0.413
2010 Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 431-9. PMID 21044773 DOI: 10.1016/J.Jalz.2010.04.003  0.447
2010 Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biological Psychiatry. 68: 876-878. PMID 21035622 DOI: 10.1016/J.Biopsych.2010.09.020  0.399
2010 Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, et al. Revising the definition of Alzheimer's disease: a new lexicon. The Lancet. Neurology. 9: 1118-27. PMID 20934914 DOI: 10.1016/S1474-4422(10)70223-4  0.449
2010 Fillit H, Cummings J, Neumann P, McLaughlin T, Salavtore P, Leibman C. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease. The Journal of Nutrition, Health & Aging. 14: 640-7. PMID 20922340 DOI: 10.1007/S12603-010-0310-8  0.347
2010 Teng E, Becker BW, Woo E, Cummings JL, Lu PH. Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment. Dementia and Geriatric Cognitive Disorders. 30: 189-97. PMID 20798539 DOI: 10.1159/000313540  0.338
2010 Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. Journal of Alzheimer's Disease : Jad. 21: 843-51. PMID 20634594 DOI: 10.3233/Jad-2010-100078  0.4
2010 Teng E, Becker BW, Woo E, Knopman DS, Cummings JL, Lu PH. Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease. Alzheimer Disease and Associated Disorders. 24: 348-53. PMID 20592580 DOI: 10.1097/Wad.0B013E3181E2Fc84  0.419
2010 Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiology of Aging. 31: 1284-303. PMID 20538372 DOI: 10.1016/J.Neurobiolaging.2010.05.003  0.323
2010 Gauthier S, Lopez OL, Waldemar G, Jones RW, Cummings J, Zhang R, Schindler R, Schwam E. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. International Psychogeriatrics / Ipa. 22: 973-83. PMID 20534179 DOI: 10.1017/S1041610210000888  0.437
2010 Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders. 29: 406-12. PMID 20502014 DOI: 10.1159/000296073  0.431
2010 Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiology of Aging. 31: 1481-92. PMID 20447734 DOI: 10.1016/J.Neurobiolaging.2010.03.016  0.431
2010 Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY, Avedissian C, Aarsland D, Janvin CC, Larsen JP, Cummings JL, Thompson PM. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 687-95. PMID 20437538 DOI: 10.1002/Mds.22799  0.361
2010 Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics. 10: 711-28. PMID 20420492 DOI: 10.1586/Ern.10.29  0.388
2010 Cummings JL. Commentary on: L-methylfolate, methylcobolamine, and N-acetylcysteine in the treatment of Alzheimer's disease-related cognitive decline. Cns Spectrums. 15: 7. PMID 20397370 DOI: 10.1017/S1092852900027607  0.376
2010 Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 25: 347-52. PMID 20392862 DOI: 10.1177/1533317510365344  0.389
2010 Cummings J, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. Journal of Alzheimer's Disease : Jad. 20: 301-11. PMID 20164585 DOI: 10.3233/Jad-2010-1362  0.462
2010 Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, et al. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. Journal of Alzheimer's Disease : Jad. 20: 509-16. PMID 20164561 DOI: 10.3233/Jad-2010-1390  0.411
2010 Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping. 31: 786-97. PMID 20143386 DOI: 10.1002/Hbm.20905  0.365
2010 Cummings JL, Ringman J, Metz K. Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative. Journal of Alzheimer's Disease : Jad. 19: 375-88. PMID 20110588 DOI: 10.3233/Jad-2010-1286  0.42
2010 Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics / Ipa. 22: 346-72. PMID 20096151 DOI: 10.1017/S1041610209991505  0.413
2010 Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, Woo E, Cummings JL, Toga AW, Jack CR, Weiner MW, Thompson PM. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage. 51: 488-99. PMID 20083211 DOI: 10.1016/J.Neuroimage.2009.12.125  0.301
2010 Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clinical Drug Investigation. 30: 41-9. PMID 19995097 DOI: 10.2165/11531270-000000000-00000  0.394
2010 Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S. Evaluation of dementia rating scales in Parkinson's disease dementia. American Journal of Alzheimer's Disease and Other Dementias. 25: 142-8. PMID 19359706 DOI: 10.1177/1533317509333904  0.446
2010 Fleisher AS, Jack CR, Weiner MW, Truran D, Mai J, Aisen PS, Cummings JL, Thomas RG, Schneider LS, Tariot PN. Brain volume changes with divalproex sodium in Alzheimer's disease Alzheimer's & Dementia. 6: S302-S303. DOI: 10.1016/J.Jalz.2010.05.988  0.367
2010 Apostolova LG, Hwang KS, Babakchanian S, Thompson PM, Cummings JL, Mulugeta E, Larsen JP, Bronnick K, Aarsland D, Alves G, Beyer MK. P1-049: Hippocampal atrophy and lateral ventricle enlargement in Parkinson's disease subjects with mild cognitive impairment Alzheimer's & Dementia. 6: S187-S188. DOI: 10.1016/J.Jalz.2010.05.596  0.39
2010 Doody RS, Tariot P, Cummings J, Winblad B, Selby B, Langenberg A, Seely L. Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.453  0.385
2010 Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Pratico D, Moskovitz J, Bitan G. P3-200: Methionine sulfoxide, an index of oxidative stress, measured in plasma of persons with familial Alzheimer's disease mutations Alzheimer's & Dementia. 6: S509-S509. DOI: 10.1016/J.Jalz.2010.05.1698  0.325
2010 Teng E, Leone-Friedman J, Woo S, Kang C, Harrell S, Cummings JL, Lu P. Similar verbal fluency patterns in amnestic mild cognitive impairment and Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.1652  0.412
2010 Woo E, Medina LD, Rodriguez-Agudelo Y, Yi D, Coppola G, Cummings JL, Ringman J. P3-099: Attention and working memory in familial Alzheimer's disease Alzheimer's & Dementia. 6: S479-S479. DOI: 10.1016/J.Jalz.2010.05.1595  0.63
2010 Nunez C, Cagigas XE, Medina L, Rodriguez-Agudelo Y, Coppola G, Cummings JL, Ringman JM. P3-094: Neuropsychological performance and demographic variables predict familial Alzheimer genetic status in a Spanish speaking sample Alzheimer's & Dementia. 6: S477-S478. DOI: 10.1016/J.Jalz.2010.05.1589  0.6
2010 Lu P, Lee GJ, Thompson PM, Medina L, Leow A, Coppola G, Cummings JL, Ringman JM. P2-381: A tensor-based morphometry study of brain volume changes in symptomatic and pre-symptomatic patients with familial Alzheimer's disease Alzheimer's & Dementia. 6: S428-S428. DOI: 10.1016/J.Jalz.2010.05.1433  0.655
2010 Ringman JM, Lee SK, Barrio J, Coppola G, Small G, Cummings JL, Silverman DH. IC-P-115: Clinical and Quantitative Fluorodeoxyglucose Positron Emission Tomography in Pre- and Symptomatic Persons Inheriting Familial Alzheimer's Disease Mutations Alzheimer's & Dementia. 6: S46-S46. DOI: 10.1016/J.Jalz.2010.05.130  0.362
2010 Woo E, Lu PH, Grill J, Cummings JL. P2-148: Neuropsychiatric symptom profiles in Mild Cognitive Impairment and Alzheimer's disease Alzheimer's & Dementia. 6: S357-S357. DOI: 10.1016/J.Jalz.2010.05.1195  0.427
2010 Braskie M, Medina L, Rodriguez-Agudelo Y, Geschwind D, Macias-Islas MA, Cummings J, Bookheimer S, Ringman J. IC-P-041: Increased fMRI Activity with Age in Left Temporal Lobe of Familial Alzheimer's Disease Mutation Carriers Alzheimer's & Dementia. 6: S20-S20. DOI: 10.1016/J.Jalz.2010.05.055  0.636
2010 Beyer MK, Hwang KS, Babakchanian S, Thompson PM, Cummings JL, Mulugeta E, Larsen JP, Bronnick KS, Aarsland D, Alves G, Apostolova LG. CSF Abeta and tau, hippocampal atrophy and lateral ventricle enlargement in Parkinson's disease with and without mild cognitive impairment Alzheimer's & Dementia. 6: S290-S291. DOI: 10.1016/J.Jalz.2010.05.047  0.377
2010 Apostolova LG, Hwang KS, Lee JJ, Gao F, Thompson PM, Ringman JM, Cummings JL, Coppola G. Gene expression correlates of hippocampal atrophy across in cognitively normal elderly and MCI Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.012  0.306
2009 Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, Lopez OL, Cummings J, Xu Y, Feldman HH. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 28: 244-51. PMID 19786776 DOI: 10.1159/000241877  0.455
2009 Fuh JL, Cummings JL. Top cited papers in International Psychogeriatrics: 6b. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. International Psychogeriatrics / Ipa. 21: 1031-6. PMID 19781110 DOI: 10.1017/S1041610209990913  0.38
2009 Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 406-18. PMID 19751920 DOI: 10.1016/J.Jalz.2008.12.003  0.417
2009 Teng E, Tingus KD, Lu PH, Cummings JL. Persistence of neuropsychological testing deficits in mild cognitive impairment. Dementia and Geriatric Cognitive Disorders. 28: 168-78. PMID 19707017 DOI: 10.1159/000235732  0.393
2009 Ringman JM, Medina LD, Rodriguez-Agudelo Y, Chavez M, Lu P, Cummings JL. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Current Alzheimer Research. 6: 341-6. PMID 19689233 DOI: 10.2174/156720509788929336  0.685
2009 Chow TW, Binns MA, Cummings JL, Lam I, Black SE, Miller BL, Freedman M, Stuss DT, van Reekum R. Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. Archives of Neurology. 66: 888-93. PMID 19597092 DOI: 10.1001/Archneurol.2009.92  0.418
2009 Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology. 72: 2115-21. PMID 19528519 DOI: 10.1212/Wnl.0B013E3181Aa52D3  0.424
2009 Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG. Management of agitation and aggression associated with Alzheimer disease. Nature Reviews. Neurology. 5: 245-55. PMID 19488082 DOI: 10.1038/Nrneurol.2009.39  0.372
2009 Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Disease and Associated Disorders. 23: 91-101. PMID 19474567 DOI: 10.1097/Wad.0B013E318191C7Dd  0.413
2009 Woods DL, Bushnell B, Kim H, Geschwind D, Cummings J. Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia. International Psychogeriatrics / Ipa. 21: 722-8. PMID 19470200 DOI: 10.1017/S1041610209009235  0.324
2009 Cummings JL. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 108-13. PMID 19328437 DOI: 10.1016/J.Jalz.2009.01.015  0.412
2009 Apostolova L, Hwang K, Andrawis J, Green A, Babakchanian S, Morra J, Cummings J, Toga A, Jack C, Weiner M, Thompson P. 3D mapping of associations between Amyloid-PET and CSF biomarkers and hippocampal morphology in normal aging and Alzheimer's disease Neuroimage. 47: S87. DOI: 10.1016/S1053-8119(09)70660-3  0.364
2009 Apostolova LG, Green AE, Babakchanian S, Hwang KS, Chou Y, Cummings JL, Toga AW, Thompson PM. Effect of age on ventricular enlargement when comparing cognitively normal elderly, mild cognitive impairment and Alzheimer's disease subjects Alzheimers & Dementia. 5. DOI: 10.1016/J.Jalz.2014.05.068  0.386
2009 Ringman JM, Medina LD, Schaffer B, Agudelo YR, Varpetian A, Macias-Islas MA, Cummings JL, Bookheimer SY. O2-01-08: Effects of ApoE genotype but not of FAD mutation status in BOLD activation during a novelty encoding task Alzheimer's & Dementia. 5: P103-P103. DOI: 10.1016/J.Jalz.2009.05.323  0.559
2009 Lu PH, Apostolova LG, Green AE, Hwang K, Chung C, Thompson PM, Leow A, Lee G, Janvin CC, Larsen JP, Cummings JL, Aarsland D, Beyer MK. A tensor based morphometry study of patients with cognitive impairment and dementia in parkinson's disease Alzheimers & Dementia. 5: 221. DOI: 10.1016/J.Jalz.2009.04.153  0.431
2009 Flores DL, Liang L, Medina LD, Agudelo YR, Schaffer B, Macias-Islas MA, Fitten LJ, Ortiz F, Cummings JL, Ringman JM. P1-072: Behavioral disturbances in early familial Alzheimer's disease Alzheimer's & Dementia. 5: P193-P193. DOI: 10.1016/J.Jalz.2009.04.076  0.654
2008 Cummings JL. Controversies in Alzheimer's disease drug development. International Review of Psychiatry (Abingdon, England). 20: 389-95. PMID 18925488 DOI: 10.1080/09540260802094548  0.427
2008 Schaffer BA, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, Bigio EH, Mesulam M, Wiedau-Pazos M, Jackson GR, Cummings JL, Cantor RM, Levey AI, Tanzi RE, Geschwind DH. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Archives of Neurology. 65: 1368-74. PMID 18852354 DOI: 10.1001/Archneur.65.10.1368  0.41
2008 Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, ... ... Cummings JL, et al. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: 156-63. PMID 18631960 DOI: 10.1016/J.Jalz.2008.03.005  0.411
2008 Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: 65-79. PMID 18631951 DOI: 10.1016/J.Jalz.2007.10.001  0.427
2008 Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: 49-60. PMID 18631950 DOI: 10.1016/J.Jalz.2007.10.011  0.376
2008 Fillit HM, Simon ES, Doniger GM, Cummings JL. Practicality of a computerized system for cognitive assessment in the elderly. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: 14-21. PMID 18631946 DOI: 10.1016/J.Jalz.2007.09.008  0.319
2008 Marshall GA, Cummings JL. Neuropsychiatric evaluation in dementia. Handbook of Clinical Neurology. 89: 53-61. PMID 18631730 DOI: 10.1016/S0072-9752(07)01204-3  0.422
2008 Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, Davies HD, Galasko D, Hewett L, Mungas D, Reed BR, Schneider LS, Segal-Gidan F, Yaffe K, Cummings JL, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 16: 469-77. PMID 18515691 DOI: 10.1097/Jgp.0B013E318165Dbae  0.318
2008 Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 71: 85-92. PMID 18509095 DOI: 10.1212/01.Wnl.0000303973.71803.81  0.63
2008 Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, Jarvik L, Kraemer HC, Lebowitz BD, Maslow K, Pollock BG, Raskind M, Schultz SK, Wang P, Zito JM, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. The Journal of Clinical Psychiatry. 69: 889-98. PMID 18494535 DOI: 10.4088/Jcp.V69N0602  0.353
2008 Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW. Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers. Dementia and Geriatric Cognitive Disorders. 25: 380-4. PMID 18376127 DOI: 10.1159/000121986  0.627
2008 Bonelli RM, Cummings JL. Frontal-subcortical dementias. The Neurologist. 14: 100-7. PMID 18332839 DOI: 10.1097/Nrl.0B013E31815B0De2  0.431
2008 Farlow MR, Cummings J. A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 25: 301-8. PMID 18311077 DOI: 10.1159/000119104  0.455
2008 Cummings JL, Miller BL, Christensen DD, Cherry D. Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease. Cns Spectrums. 13: 1-20; quiz 22. PMID 18264030  0.345
2008 Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dementia and Geriatric Cognitive Disorders. 25: 115-26. PMID 18087152 DOI: 10.1159/000112509  0.37
2008 Apostolova LG, Lu P, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease. Brain and Language. 104: 33-41. PMID 17485107 DOI: 10.1016/J.Bandl.2007.03.008  0.351
2008 Tsang SW, Vinters HV, Cummings JL, Wong PT, Chen CP, Lai MK. Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiology of Aging. 29: 1524-32. PMID 17433503 DOI: 10.1016/J.Neurobiolaging.2007.03.014  0.353
2008 Cummings JL. Update on Alzheimer's disease: One hundred years after Dr. Alois Alzheimer Primary Psychiatry. 15: 4-6. DOI: 10.1017/S1092852900002819  0.433
2008 Ringman JM, Medina L, Rodriguez Y, Schaffer B, Varpetian A, Macias-Islas MA, Cummings JL, Bookheimer S. P1-282: Decreased activation in the left medial parietal lobe in presymptomatic familial Alzheimer's disease mutation carriers in FMRI during an unrelated word pair memory task Alzheimer's & Dementia. 4: T299-T300. DOI: 10.1016/J.Jalz.2008.05.872  0.625
2008 Lu P, Edland S, Teng E, Tingus K, Thal L, Cummings J. P1-194: Effects of donepezil on the relationship between depression and progression to Alzheimer's disease in patients with mild cognitive impairment Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.782  0.421
2008 Apostolova LG, Beyer MK, Green AE, Chou Y, Morra JH, Hwang K, Aarsland D, Janvin CC, Larsen JP, Toga AW, Cummings JL, Thompson PM. IC-P2-072: Automated 3D mapping of caudate atrophy and ventricular enlargement in Parkinson's disease with and without dementia Alzheimer's & Dementia. 4: T37-T37. DOI: 10.1016/J.Jalz.2008.05.2616  0.343
2008 Ringman JM, Cole G, Teng E, Badmaev V, Bardens J, Frautschy S, Rosario E, Fein J, Porter V, Vanek Z, Sugar C, Yau A, Cummings JL. P4-344: Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: Tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study Alzheimer's & Dementia. 4: T774-T774. DOI: 10.1016/J.Jalz.2008.05.2414  0.338
2008 Cummings J, Doody R, Gavrilova S, Sano M, Aisen P, Seely L, Hung D. P4-334: Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2404  0.383
2008 Stender K, Cummings J. P4-329: Post HOC responder analyses of Memantine treatment on behavioral disturbances in patients with moderate to severe Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2399  0.413
2008 Feldman H, Cummings J, Schwam E, Jones RW, Wilkinson D, Waldemar G, Zhang R, Schindler R. P4-314: Evaluating neuropsychiatric symptoms in Alzheimer's disease: A novel approach using bubble plots to evaluate donepezil treatment effects Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2384  0.368
2008 Apostolova LG, Morra JH, Green AH, Hwang K, Avedissian C, Parikshak N, Cummings JL, Toga AW, Jack CR, Weiner MW, Thompson PM. O1-02-05: Automated longitudinal 3D mapping of hippocampal ADAS-cog delayed recall effects in 293 normal elderly, MCI and Alzheimer's disease subjects Alzheimer's & Dementia. 4: T110-T110. DOI: 10.1016/J.Jalz.2008.05.224  0.355
2008 Thompson P, Apostolova LG, Morra JH, Green AE, Hwang K, Avedissian C, Parikshak N, Cummings JL, Toga AW, Jack CR, Weiner MW. IC-P3-223: Automated longitudinal 3D mapping of hippocampal ADASCPG delayed recall effects in 293 normal elderly, MCI and AD subjects Alzheimer's & Dementia. 4: T95-T95. DOI: 10.1016/J.Jalz.2008.05.168  0.397
2008 Ringman JM, Medina L, Rodriguez Y, Schaffer B, Varpetian A, Macias-Islas MA, Cummings JL, Bookheimer S. IC-P3-207: Decreased activation in the left medial parietal lobe in presymptomatic FAD mutation carriers in fMRI during an unrelated word pair memory task Alzheimer's & Dementia. 4: T89-T89. DOI: 10.1016/J.Jalz.2008.05.151  0.624
2007 Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review of Neurotherapeutics. 7: 1457-63. PMID 17997695 DOI: 10.1586/14737175.7.11.1457  0.406
2007 Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 69: 1622-34. PMID 17938373 DOI: 10.1212/01.Wnl.0000295996.54210.69  0.423
2007 Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Archives of Neurology. 64: 1489-95. PMID 17923632 DOI: 10.1001/Archneur.64.10.1489  0.454
2007 Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA, Reiman EM, Kowall N, Landreth G, Shelanski M, Welsh-Bohmer K, ... ... Cummings JL, et al. The National Alzheimer's Coordinating Center (NACC) database: The uniform data set Alzheimer Disease and Associated Disorders. 21: 249-258. PMID 17804958 DOI: 10.1097/Wad.0B013E318142774E  0.352
2007 Cummings JL. Measuring disease modification in Alzheimer's disease. Cns Spectrums. 12: 11-4. PMID 17712916 DOI: 10.1017/S109285290002589X  0.396
2007 Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 24: 253-9. PMID 17700021 DOI: 10.1159/000107100  0.467
2007 Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. Journal of Alzheimer's Disease : Jad. 11: 509-19. PMID 17656830 DOI: 10.3233/Jad-2007-11412  0.468
2007 Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch Neurology. 69: S10-S13. PMID 17646618 DOI: 10.1212/01.Wnl.0000281846.40390.50  0.332
2007 Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Archives of Neurology. 64: 1015-20. PMID 17620493 DOI: 10.1001/Archneur.64.7.1015  0.398
2007 Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet. Neurology. 6: 734-46. PMID 17616482 DOI: 10.1016/S1474-4422(07)70178-3  0.42
2007 Apostolova LG, Akopyan GG, Partiali N, Steiner CA, Dutton RA, Hayashi KM, Dinov ID, Toga AW, Cummings JL, Thompson PM. Structural correlates of apathy in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 24: 91-7. PMID 17570907 DOI: 10.1159/000103914  0.407
2007 Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1689-707; quiz 1837. PMID 17542011 DOI: 10.1002/Mds.21507  0.322
2007 Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, Schaffer B, Varpetian A, Tseng B, Ortiz F, Fitten J, Cummings JL, Bartzokis G. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain : a Journal of Neurology. 130: 1767-76. PMID 17522104 DOI: 10.1093/Brain/Awm102  0.615
2007 Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet. Neurology. 6: 501-12. PMID 17509485 DOI: 10.1016/S1474-4422(07)70109-6  0.439
2007 Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. The American Journal of Medicine. 120: 388-97. PMID 17466645 DOI: 10.1016/J.Amjmed.2006.08.036  0.433
2007 Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism Neurology. 68: 1356-1363. PMID 17452579 DOI: 10.1212/01.Wnl.0000260060.60870.89  0.384
2007 Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry. 22: 456-67. PMID 17380489 DOI: 10.1002/Gps.1788  0.387
2007 Teng E, Lu PH, Cummings JL. Deficits in facial emotion processing in mild cognitive impairment. Dementia and Geriatric Cognitive Disorders. 23: 271-9. PMID 17351319 DOI: 10.1159/000100829  0.35
2007 Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer's disease is associated with greater pathologic burden. Journal of Geriatric Psychiatry and Neurology. 20: 29-33. PMID 17341768 DOI: 10.1177/0891988706297086  0.423
2007 Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Annals of Neurology. 61: 92-6. PMID 17212357 DOI: 10.1002/Ana.21056  0.306
2007 Tsang SW, Pomakian J, Marshall GA, Vinters HV, Cummings JL, Chen CP, Wong PT, Lai MK. Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiology of Aging. 28: 1381-7. PMID 16828202 DOI: 10.1016/J.Neurobiolaging.2006.06.001  0.303
2007 Cummings JL. The neuropsychiatric disturbances in demential disorders or behavioral and psychological symptoms of dementia Jornal Brasileiro De Psiquiatria. 56: 81-82. DOI: 10.1590/S0047-20852007000200001  0.323
2007 Cummings J. A transdermal patch in Alzheimer disease Neurology. 69: S2-S3. DOI: 10.1212/01.Wnl.0000281844.32766.24  0.373
2007 Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, Thompson PM, Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, et al. Disease mechanisms in neuroscience Neuroscientist. 13: 99. DOI: 10.1177/10738584070130020301  0.312
2007 Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Erratum: 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease (Brain (2006) 127, part 11, (2867-2873) DOI: 10.1093/brain/awl274) Brain. 130. DOI: 10.1093/Brain/Awm182  0.376
2007 Tariot PN, Thal L, Jakimovich L, Schneider L, Cummings J, Raman R, Edland S. P-205: Valproate therapy to attenuate the clinical progression of Alzheimer's disease: Design of the ADCS valproate neuroprotection trial Alzheimer's & Dementia. 3: S163-S164. DOI: 10.1016/J.Jalz.2007.04.110  0.38
2007 Senanarong V-, Harnphadungkit K-, Poungvarin N, Cummings JL, Doody RS. O1-05-06: The dementia and disability in thai elderly project: Prevalence of mild cognitive impairment with one year follow up and the prevalence of dementia in community dwelling thai elderly Alzheimer's & Dementia. 3: S178-S178. DOI: 10.1016/J.Jalz.2007.04.073  0.339
2006 Tractenberg RE, Aisen PS, Weiner MF, Cummings JL, Hancock GR. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 303-13. PMID 19595904 DOI: 10.1016/J.Jalz.2006.08.001  0.345
2006 Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 263-71. PMID 19595897 DOI: 10.1016/J.Jalz.2006.07.001  0.41
2006 Tariot PN, Cummings JL, Ismail MS, Lyketsos C. New paradigms in the treatment of Alzheimer's disease The Journal of Clinical Psychiatry. 67: 2002-2013. PMID 17194280 DOI: 10.4088/Jcp.V67N1222  0.395
2006 Cummings JL, Raman R, Ernstrom K, Salmon D, Ferris SH. ADCS Prevention Instrument Project: behavioral measures in primary prevention trials. Alzheimer Disease and Associated Disorders. 20: S147-51. PMID 17135808 DOI: 10.1097/01.Wad.0000213872.17429.0F  0.413
2006 Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Disease and Associated Disorders. 20: S109-23. PMID 17135805 DOI: 10.1097/01.Wad.0000213870.40300.21  0.398
2006 Fuh JL, Lam L, Hirono N, Senanarong V, Cummings JL. Neuropsychiatric inventory workshop: behavioral and psychologic symptoms of dementia in Asia. Alzheimer Disease and Associated Disorders. 20: 314-7. PMID 17132981 DOI: 10.1097/01.Wad.0000213853.04861.02  0.345
2006 Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ. Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials. Alzheimer Disease and Associated Disorders. 20: 232-41. PMID 17132967 DOI: 10.1097/01.Wad.0000213862.20108.F5  0.439
2006 Apostolova LG, Lu PH, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease. Alzheimer Disease and Associated Disorders. 20: 224-31. PMID 17132966 DOI: 10.1097/01.Wad.0000213857.89613.10  0.413
2006 Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Disease and Associated Disorders. 20: 210-6. PMID 17132964 DOI: 10.1097/01.Wad.0000213865.09806.92  0.4
2006 Maurer K, McKeith I, Cummings J, Ames D, Burns A. Has the management of Alzheimer's disease changed over the past 100 years? The Lancet. 368: 1619-1621. PMID 17084762 DOI: 10.1016/S0140-6736(06)69663-3  0.358
2006 Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain : a Journal of Neurology. 129: 2867-73. PMID 17018552 DOI: 10.1093/Brain/Awl274  0.415
2006 Ortiz F, Fitten LJ, Cummings JL, Hwang S, Fonseca M. Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 21: 263-73. PMID 16948291 DOI: 10.1177/1533317506289350  0.397
2006 Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics. 7: 277-9. PMID 16897084 DOI: 10.1007/S10048-006-0053-1  0.602
2006 Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 67: 57-63. PMID 16832078 DOI: 10.1212/01.Wnl.0000223333.42368.F1  0.398
2006 Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 605-12. PMID 16816014 DOI: 10.1097/01.Jgp.0000221293.91312.D3  0.39
2006 Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behavioural Neurology. 17: 5-16. PMID 16720956 DOI: 10.1155/2006/315386  0.466
2006 Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Archives of Neurology. 63: 693-9. PMID 16682538 DOI: 10.1001/Archneur.63.5.693  0.425
2006 Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, et al. Mild cognitive impairment. Lancet. 367: 1262-70. PMID 16631882 DOI: 10.1016/S0140-6736(06)68542-5  0.393
2006 Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of activities of daily living in Alzheimer disease. Alzheimer Disease and Associated Disorders. 20: 56-9. PMID 16493237 DOI: 10.1097/01.Wad.0000201852.60330.16  0.422
2006 Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nature Reviews. Drug Discovery. 5: 64-74. PMID 16485346 DOI: 10.1038/Nrd1928  0.335
2006 Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America. 103: 702-7. PMID 16407119 DOI: 10.1073/Pnas.0510237103  0.346
2006 Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 21: 144-7. PMID 16391476 DOI: 10.1159/000090674  0.423
2006 Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mintz J, Cummings JL. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Archives of General Psychiatry. 63: 63-72. PMID 16389198 DOI: 10.1001/Archpsyc.63.1.63  0.337
2006 Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V, Swerdloff R, Cummings JL. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Archives of Neurology. 63: 177-85. PMID 16344336 DOI: 10.1001/Archneur.63.2.Nct50002  0.359
2006 Van Lancker Sidtis D, Pachana N, Cummings JL, Sidtis JJ. Dysprosodic speech following basal ganglia insult: toward a conceptual framework for the study of the cerebral representation of prosody. Brain and Language. 97: 135-53. PMID 16271755 DOI: 10.1016/J.Bandl.2005.09.001  0.31
2006 Raya-Ampil E, Cummings JL. Clinical Trials in Dementia Progress in Neurotherapeutics and Neuropsychopharmacology. 2: 39-78. DOI: 10.1017/S174823210600005X  0.377
2006 Cummings JL. Introduction to Neurotherapeutics and Neuropsychopharmacology Progress in Neurotherapeutics and Neuropsychopharmacology. 1: 1-12. DOI: 10.1017/S1748232105000029  0.333
2006 Cummings JL, Johansson JO, Kulikowski E, Wong NC, Halliday C, Lebioda K, Winblad B, Zetterberg H, Kalantar-Zadeh K, Nicholls SJ, Schwartz GG, Ray KK, Sweeney M. P2-037: APABETALONE (AN EPIGENETIC BET-INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE Alzheimer's & Dementia. 14: P680-P681. DOI: 10.1016/J.Jalz.2018.06.721  0.307
2006 Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, Raket LL, Tariot PN. P3-003: IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER'S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS Alzheimer's & Dementia. 14: P1062-P1063. DOI: 10.1016/J.Jalz.2018.06.1358  0.372
2006 Cummings JL, Grossberg GT, Porsteinsson AP, Hendrix S, Ellison N, Kerolous M. P1-069: THE EFFECTS OF MEMANTINE ADDED TO CHOLINESTERASE INHIBITORS ON NPI BEHAVIORAL DOMAINS: POOLED POST HOC ANALYSIS OF THREE RANDOMIZED CONTROLLED TRIALS IN PATIENTS WITH MODERATE TO SEVERE AD Alzheimer's & Dementia. 14: P297-P297. DOI: 10.1016/J.Jalz.2018.06.054  0.364
2006 Cummings JL, Olin JT. P1-456: The effect of memantine on distinct behavior syndromes in moderate to severe AD patients Alzheimer's & Dementia. 2: S231-S232. DOI: 10.1016/J.Jalz.2006.05.835  0.354
2006 Cummings JL, Olin JT. P1-455: Meta-analysis of Neuropsychiatric Inventory (NPI) domains in three 6-month trials of memantine in moderate to severe AD Alzheimer's & Dementia. 2: S231-S231. DOI: 10.1016/J.Jalz.2006.05.834  0.33
2006 Simon ES, Doniger GM, Cummings JL, Fillit H. O4-04-01: A hierarchical approach to practical assessment of cognitive decline in the elderly Alzheimer's & Dementia. 2: S82-S82. DOI: 10.1016/J.Jalz.2006.05.318  0.327
2006 Ringman JM, O'Neill J, Tseng B, Rodriguez Y, Geschwind D, Schaffer B, Medina L, Thixton T, Cummings JL. IC-P-090: Elevated hippocampal myo-inositol in subjects with or at-risk for familial AD Alzheimer's & Dementia. 2: S689-S689. DOI: 10.1016/J.Jalz.2006.05.2295  0.611
2006 Ringman JM, O'Neill J, Apostolova L, Geschwind D, Tseng B, Schaffer B, Rodriguez Y, Medina L, Cummings JL, Bartzokis G. IC-P-069: Decreased fractional anisotropy in the fornix of presymptomatic carriers of FAD mutations Alzheimer's & Dementia. 2: S680-S680. DOI: 10.1016/J.Jalz.2006.05.2274  0.563
2006 Apostolova LG, Clark DG, Zoumalan C, Steiner CA, McMurtray A, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Mendez MF, Thompson PM. IC-P-018: 3D mapping of gray matter atrophy in semantic dementia and frontal variant frontotemporal dementia Alzheimer's & Dementia. 2: S661-S662. DOI: 10.1016/J.Jalz.2006.05.1213  0.33
2006 Barrio JR, Kepe V, Huang S, Ercoli L, Siddarth P, Cole GM, Satyamurthy N, Cummings JL, Phelps ME, Small GW. P2-300: In vivo quantification of neuronal loss and neuropathological deposition in Alzheimer's disease with PET Alzheimer's & Dementia. 2: S328-S328. DOI: 10.1016/J.Jalz.2006.05.1139  0.346
2006 Ringman JM, Cole G, Geschwind D, Schaffer B, Rodriguez Y, Fein J, Medina L, Pratico D, Younkin S, Cummings JL. P2-164: Biochemical markers in blood and cerebrospinal fluid of persons with or at-risk for familial AD Alzheimer's & Dementia. 2: S282-S282. DOI: 10.1016/J.Jalz.2006.05.1002  0.61
2005 Cummings JL. Clinical evaluation as a biomarker for Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 8: 327-37. PMID 16556964 DOI: 10.3233/Jad-2005-8402  0.347
2005 Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer's disease. Cns Spectrums. 10: 22-5. PMID 16273027 DOI: 10.1017/S1092852900014206  0.43
2005 Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. The American Journal of Geriatric Pharmacotherapy. 3: 137-48. PMID 16257816 DOI: 10.1016/S1543-5946(05)80020-0  0.458
2005 Cummings JL. The neuropsychiatric burden of neurological diseases in the elderly. International Psychogeriatrics / Ipa. 17: 341-51. PMID 16252369 DOI: 10.1017/S1041610205002206  0.374
2005 McKeith I, Cummings JL. Behavioural changes and psychological symptoms in dementia disorders Lancet Neurology. 4: 735-742. PMID 16239180 DOI: 10.1016/S1474-4422(05)70219-2  0.389
2005 McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 65: 1863-72. PMID 16237129 DOI: 10.1212/01.Wnl.0000187889.17253.B1  0.403
2005 Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia. Journal of Neurology, Neurosurgery, and Psychiatry. 76: 1337-41. PMID 16170072 DOI: 10.1136/jnnp.2004.056408  0.346
2005 Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 7: 235-9; discussion 25. PMID 16006667 DOI: 10.3233/Jad-2005-7306  0.408
2005 Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Current Alzheimer Research. 2: 131-6. PMID 15974909 DOI: 10.2174/1567205053585882  0.401
2005 Cummings JL. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 76: 903-4. PMID 15965192 DOI: 10.1136/Jnnp.2004.061499  0.362
2005 Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 13: 469-74. PMID 15956266 DOI: 10.1097/00019442-200506000-00005  0.366
2005 Senanarong V, Poungvarin N, Jamjumras P, Sriboonroung A, Danchaivijit C, Udomphanthuruk S, Cummings JL. Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease. International Psychogeriatrics / Ipa. 17: 81-90. PMID 15945593 DOI: 10.1017/S1041610205000980  0.345
2005 Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Amezcua H, Cummings JL. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Archives of Neurology. 62: 721-8. PMID 15883258 DOI: 10.1001/Archneur.62.5.721  0.403
2005 Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 53: 695-9. PMID 15817019 DOI: 10.1111/J.1532-5415.2005.53221.X  0.324
2005 Cummings JL. Searching for methods to detect, prevent, and treat Alzheimer's disease. The American Journal of Psychiatry. 162: 645-7. PMID 15800132 DOI: 10.1176/Appi.Ajp.162.4.645  0.371
2005 Tractenberg RE, Weiner MF, Cummings JL, Patterson MB, Thal LJ. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. The Journal of Neuropsychiatry and Clinical Neurosciences. 17: 51-60. PMID 15746483 DOI: 10.1176/Jnp.17.1.51  0.422
2005 Cummings JL. Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease Neurology. 65: S18-S24. DOI: 10.1212/Wnl.65.6_Suppl_3.S18  0.468
2005 Cummings JL, Schneider E, Peskind ER, Tariot PN, Graham SM, Bell JM. [P-194]: Effect of memantine on behavioral outcomes in Alzheimer's disease Alzheimer's & Dementia. 1: S70-S70. DOI: 10.1016/J.Jalz.2005.06.253  0.419
2005 Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mintz J, Cummings JL. [P-063]: The impact of ApoE alleles on age-related myelin breakdown Alzheimer's & Dementia. 1: S28-S28. DOI: 10.1016/J.Jalz.2005.06.137  0.309
2005 Cummings JL, Altman J. Genotype — Proteotype — Phenotype Relationships in Neurodegenerative Diseases Reviews in Neurological Diseases. 2: 80-84. DOI: 10.1007/B137738  0.316
2004 Cummings JL, Tractenberg RE, Gamst A, Teri L, Masterman D, Thal LJ. Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Current Alzheimer Research. 1: 323-8. PMID 15975061 DOI: 10.2174/1567205043332027  0.362
2004 Assal F, Alarcón M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Archives of Neurology. 61: 1249-53. PMID 15313842 DOI: 10.1001/Archneur.61.8.1249  0.307
2004 Cummings JL. Dementia with lewy bodies: molecular pathogenesis and implications for classification. Journal of Geriatric Psychiatry and Neurology. 17: 112-9. PMID 15312274 DOI: 10.1177/0891988704267473  0.399
2004 Senanarong V, Jamjumras P, Harmphadungkit K, Klubwongs M, Udomphanthurak S, Poungvarin N, Vannasaeng S, Cummings JL. A counseling intervention for caregivers: effect on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry. 19: 781-8. PMID 15290702 DOI: 10.1002/Gps.1123  0.35
2004 Cummings JL. Alzheimer's disease. The New England Journal of Medicine. 351: 56-67. PMID 15229308 DOI: 10.1056/NEJMra040223  0.306
2004 Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiology of Aging. 25: 843-51. PMID 15212838 DOI: 10.1016/J.Neurobiolaging.2003.09.005  0.329
2004 Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Disease and Associated Disorders. 18: 17-21. PMID 15195459 DOI: 10.1097/00002093-200401000-00004  0.429
2004 Bartzokis G, Tishler TA, Shin IS, Lu PH, Cummings JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Annals of the New York Academy of Sciences. 1012: 224-36. PMID 15105269 DOI: 10.1196/Annals.1306.019  0.352
2004 Cummings JL. Fluctuations in cognitive function in dementia with Lewy bodies. The Lancet. Neurology. 3: 266. PMID 15099536 DOI: 10.1016/S1474-4422(04)00728-8  0.41
2004 Waltz JA, Knowlton BJ, Holyoak KJ, Boone KB, Back-Madruga C, McPherson S, Masterman D, Chow T, Cummings JL, Miller BL. Relational integration and executive function in Alzheimer's disease. Neuropsychology. 18: 296-305. PMID 15099152 DOI: 10.1037/0894-4105.18.2.296  0.402
2004 Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL. Executive dysfunction in Alzheimer disease. Archives of Neurology. 61: 556-60. PMID 15096405 DOI: 10.1001/Archneur.61.4.556  0.467
2004 Kang SJ, Choi SH, Lee BH, Jeong Y, Hahm DS, Han IW, Cummings JL, Na DL. Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). Journal of Geriatric Psychiatry and Neurology. 17: 32-5. PMID 15018695 DOI: 10.1177/089198873258818  0.334
2004 Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. The American Journal of Psychiatry. 161: 532-8. PMID 14992980 DOI: 10.1176/Appi.Ajp.161.3.532  0.424
2004 Cummings JL. The one-minute mental status examination. Neurology. 62: 534-5. PMID 14981165 DOI: 10.1212/Wnl.62.4.534  0.31
2004 Cummings JL, Silverman D, Small G, Phelps M. The role of positron emission tomography in the diagnosis of Alzheimer's disease. Journal of the American Geriatrics Society. 52: 467-8; author reply . PMID 14962169 DOI: 10.1111/J.1532-5415.2004.52125_2.X  0.353
2004 Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Archives of Pathology & Laboratory Medicine. 128: 32-8. PMID 14692815 DOI: 10.1043/1543-2165(2004)128<32:Cid>2.0.Co;2  0.416
2004 Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 17: 100-8. PMID 14564129 DOI: 10.1159/000074281  0.435
2004 Senanarong V, Cummings JL, Fairbanks L, Mega M, Masterman DM, O'Connor SM, Strickland TL. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dementia and Geriatric Cognitive Disorders. 17: 14-20. PMID 14560060 DOI: 10.1159/000074080  0.483
2004 Aarsland D, Cummings JL. Psychiatric Aspects of Parkinson’s Disease, Parkinson’s Disease with Dementia, and Dementia with Lewy Bodies: Journal of Geriatric Psychiatry and Neurology. 17: 111-111. DOI: 10.1177/0891988704267454  0.408
2004 Cummings JL. Advances in the Neuropsychopharmacologic Management of Behavioral Alterations in Alzheimer’s Disease Dementia and Geriatric Cognitive Disorders. 17: 54-54. DOI: 10.1159/000074276  0.375
2004 Cummings JL. Long-Term Treatment for Patients with Alzheimer Disease Alzheimer Disease & Associated Disorders. 18: S1. DOI: 10.1097/01.Wad.0000127491.57408.4C  0.351
2004 Cummings J, Dyck Cv, Schmitt F, Graham SM, Olin JT, Jin J, Tariot PN. P1-315 Functional and behavioral effects of memantine in Alzheimer's disease Neurobiology of Aging. 25: S186. DOI: 10.1016/S0197-4580(04)80628-6  0.393
2004 Cummings JL. The Dementias: Diagnosis, Treatment and Research, 3rd ed Archives of Neurology. 61: 1623. DOI: 10.1001/Archneur.61.10.1623-A  0.309
2003 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, et al. Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. Expert Review of Neurotherapeutics. 3: 99-106. PMID 19810852 DOI: 10.1586/14737175.3.1.99  0.39
2003 Silverman DH, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Molecular Genetics and Metabolism. 80: 350-5. PMID 14680983 DOI: 10.1016/S1096-7192(03)00139-2  0.328
2003 Gustavson AR, Cummings JL. Cholinesterase inhibitors in non-Alzheimer dementias. Journal of the American Medical Directors Association. 4: S165-9. PMID 14613594 DOI: 10.1016/S1525-8610(04)70409-0  0.387
2003 Mendez MF, Clark DG, Shapira JS, Cummings JL. Speech and language in progressive nonfluent aphasia compared with early Alzheimer's disease. Neurology. 61: 1108-13. PMID 14581673 DOI: 10.1212/01.Wnl.0000090563.97453.90  0.4
2003 Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Annals of Neurology. 54: 147-54. PMID 12891666 DOI: 10.1002/Ana.10616  0.354
2003 Solomon DH, Wenger NS, Saliba D, Young RT, Adelman AM, Besdine RK, Blazer DG, Cassell CK, Cummings JL, Katz PR, Kitzman DW, Lavizzo-Mourey RJ, Mondoux LC, Popovich R, Pories WJ, et al. Appropriateness of quality indicators for older patients with advanced dementia and poor prognosis. Journal of the American Geriatrics Society. 51: 902-7. PMID 12834508 DOI: 10.1046/J.1365-2389.2003.513331.X  0.31
2003 Cummings JL. The impact of depressive symptoms on patients with Alzheimer disease. Alzheimer Disease and Associated Disorders. 17: 61-2. PMID 12794380 DOI: 10.1097/00002093-200304000-00001  0.355
2003 Sobrido MJ, Miller BL, Havlioglu N, Zhukareva V, Jiang Z, Nasreddine ZS, Lee VM, Chow TW, Wilhelmsen KC, Cummings JL, Wu JY, Geschwind DH. Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. Archives of Neurology. 60: 698-702. PMID 12756133 DOI: 10.1001/Archneur.60.5.698  0.319
2003 Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. The American Journal of Psychiatry. 160: 857-66. PMID 12727688 DOI: 10.1176/Appi.Ajp.160.5.857  0.412
2003 Porter VR, Buxton WG, Fairbanks LA, Strickland T, O'Connor SM, Rosenberg-Thompson S, Cummings JL. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. The Journal of Neuropsychiatry and Clinical Neurosciences. 15: 180-6. PMID 12724459 DOI: 10.1176/Jnp.15.2.180  0.437
2003 Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Archives of Neurology. 60: 393-8. PMID 12633151 DOI: 10.1001/Archneur.60.3.393  0.335
2003 Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 11: 214-21. PMID 12611751 DOI: 10.1097/00019442-200303000-00012  0.44
2003 Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 11: 131-45. PMID 12611743 DOI: 10.1097/00019442-200303000-00004  0.346
2003 Cummings JL. Alzheimer's disease: from molecular biology to neuropsychiatry. Seminars in Clinical Neuropsychiatry. 8: 31-6. PMID 12567330 DOI: 10.1053/Scnp.2003.50005  0.426
2003 Sultzer DL, Brown CV, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, Cummings JL. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. The American Journal of Psychiatry. 160: 341-9. PMID 12562582 DOI: 10.1176/Appi.Ajp.160.2.341  0.42
2003 Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, Cummings JL, Effros RB. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiology of Aging. 24: 77-84. PMID 12493553 DOI: 10.1016/S0197-4580(02)00043-X  0.349
2002 Silverman DH, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, Phelps ME. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 4: 283-93. PMID 14537119 DOI: 10.1016/S1536-1632(02)00016-1  0.338
2002 Back-Madruga C, Boone KB, Briere J, Cummings J, McPherson S, Fairbanks L, Thompson E. Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease. The Clinical Neuropsychologist. 16: 331-40. PMID 12607146 DOI: 10.1076/Clin.16.3.331.13846  0.457
2002 Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, LaFrance WC, Coffey CE. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. The Journal of Neuropsychiatry and Clinical Neurosciences. 14: 377-405. PMID 12426407 DOI: 10.1176/JNP.14.4.377  0.31
2002 Fuh JL, Mega MS, Binetti G, Wang SJ, Magni E, Cummings JL. A transcultural study of agitation in dementia. Journal of Geriatric Psychiatry and Neurology. 15: 171-4. PMID 12230087 DOI: 10.1177/089198870201500308  0.384
2002 Aarsland D, Cummings JL. Depression in Parkinson's disease. Acta Psychiatrica Scandinavica. 106: 161-2. PMID 12197850 DOI: 10.1034/J.1600-0447.2002.2E009.X  0.311
2002 Sultzer DL, Chen ST, Brown CV, Mahler ME, Cummings JL, Hinkin CH, Mandelkern MA. Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings. The Journal of Neuropsychiatry and Clinical Neurosciences. 14: 262-9. PMID 12154149 DOI: 10.1176/Jnp.14.3.262  0.402
2002 Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Current Opinion in Neurology. 15: 445-50. PMID 12151841 DOI: 10.1097/00019052-200208000-00007  0.411
2002 Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Safety. 25: 511-23. PMID 12093309 DOI: 10.2165/00002018-200225070-00005  0.387
2002 Rosen HJ, Hartikainen KM, Jagust W, Kramer JH, Reed BR, Cummings JL, Boone K, Ellis W, Miller C, Miller BL. Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD. Neurology. 58: 1608-15. PMID 12058087 DOI: 10.1212/Wnl.58.11.1608  0.395
2002 Cummings JL, Cole G. Alzheimer disease. Jama. 287: 2335-8. PMID 11988038  0.306
2002 McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C. Apathy and executive function in Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 8: 373-81. PMID 11939696 DOI: 10.1017/S1355617702813182  0.418
2002 Cummings J, Farlow M, Geula C, Korczyn A, McKeith I, Nordberg A, Tariot P, Robert P, Burns A. Understanding changes in cholinergic function: Implications for treating dementia Journal of Clinical Psychiatry. 63: 259-269. PMID 11926730 DOI: 10.4088/Jcp.V63N0316  0.333
2002 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, et al. Provisional diagnostic criteria for depression of Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 125-8. PMID 11925273 DOI: 10.1097/00019442-200203000-00003  0.384
2002 Senanarong V, Vannasaeng S, Poungvarin N, Ploybutr S, Udompunthurak S, Jamjumras P, Fairbanks L, Cummings JL. Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. Archives of Neurology. 59: 385-9. PMID 11890841 DOI: 10.1001/Archneur.59.3.385  0.308
2002 Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 57: M173-7. PMID 11867654 DOI: 10.1093/Gerona/57.3.M173  0.381
2002 Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dementia and Geriatric Cognitive Disorders. 13: 67-73. PMID 11844887 DOI: 10.1159/000048636  0.337
2002 Pang FC, Chow TW, Cummings JL, Leung VP, Chiu HF, Lam LC, Chen QL, Tai CT, Chen LW, Wang SJ, Fuh JL. Effect of neuropsychiatric symptoms of Alzheimer's disease on Chinese and American caregivers. International Journal of Geriatric Psychiatry. 17: 29-34. PMID 11802227 DOI: 10.1002/Gps.510  0.412
2001 Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society. 49: 1590-9. PMID 11843990 DOI: 10.1111/J.1532-5415.2001.49266.X  0.373
2001 Geschwind DH, Robidoux J, Alarcón M, Miller BL, Wilhelmsen KC, Cummings JL, Nasreddine ZS. Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. Annals of Neurology. 50: 741-6. PMID 11761471 DOI: 10.1002/Ana.10024  0.302
2001 Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, ... ... Cummings JL, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. Jama. 286: 2120-7. PMID 11694153 DOI: 10.1001/Jama.286.17.2120  0.426
2001 Leung VP, Lam LC, Chiu HF, Cummings JL, Chen QL. Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). International Journal of Geriatric Psychiatry. 16: 789-93. PMID 11536346 DOI: 10.1002/Gps.427  0.344
2001 Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 71: 310-4. PMID 11511702 DOI: 10.1136/Jnnp.71.3.310  0.349
2001 Cummings JL, McPherson S. Neuropsychiatric assessment of Alzheimer's disease and related dementias. Aging (Milan, Italy). 13: 240-6. PMID 11444257 DOI: 10.1007/Bf03351482  0.436
2001 Cummings JL. Treatment of Alzheimer's disease. Clinical Cornerstone. 3: 27-39. PMID 11432120 DOI: 10.1016/S1098-3597(01)90046-8  0.428
2001 Cummings JL, Nadel A, Masterman D, Cyrus PA. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology. 14: 101-8. PMID 11419566 DOI: 10.1177/089198870101400211  0.394
2001 Fuh JL, Liu CK, Mega MS, Wang SJ, Cummings JL. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. International Psychogeriatrics / Ipa. 13: 121-8. PMID 11352329 DOI: 10.1017/S1041610201007517  0.441
2001 Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56: 1154-66. PMID 11342679 DOI: 10.1212/Wnl.56.9.1154  0.373
2001 Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56: 1133-42. PMID 11342677 DOI: 10.1212/Wnl.56.9.1133  0.377
2001 Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, Cummings JL. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Annals of Neurology. 49: 355-61. PMID 11261510 DOI: 10.1002/Ana.72  0.348
2001 Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry. 16: 184-91. PMID 11241724 DOI: 10.1002/1099-1166(200102)16:2<184::Aid-Gps304>3.0.Co;2-K  0.457
2001 Tekin S, Fairbanks LA, O'Connor S, Rosenberg S, Cummings JL. Activities of daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness influences. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 81-6. PMID 11156757 DOI: 10.1097/00019442-200102000-00013  0.422
2001 Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Cummings JL, Toga AW. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cerebral Cortex (New York, N.Y. : 1991). 11: 1-16. PMID 11113031 DOI: 10.1093/Cercor/11.1.1  0.352
2001 Cummings JL, Senanarong V. Geriatric Neuropsychopharmacology: Unmet Needs Psychogeriatrics. 1: 14-26. DOI: 10.1111/J.1479-8301.2001.Tb00069.X  0.359
2001 Tekin S, Cummings JL. DEPRESSION IN DEMENTIA The Neurologist. 7: 252-259. DOI: 10.1097/00127893-200107000-00005  0.366
2001 Thompson PM, Zubicaray Gd, Janke AL, Rose SE, Dittmer S, Semple J, Gravano D, Han S, Herman D, Hong MS, Mega MS, Cummings JL, Doddrell DM, Toga AW. Detecting dynamic (4D) profiles of degenerative rates in Alzheimer's disease patients, using high-resolution tensor mapping and a brain atlas encoding atrophic rates in a population Neuroimage. 13: 849. DOI: 10.1016/S1053-8119(01)92191-3  0.312
2000 Cummings JL. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 3: 21-29. PMID 11343621 DOI: 10.1017/S1461145700001917  0.436
2000 Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiology of Aging. 21: 845-61. PMID 11124429 DOI: 10.1016/S0197-4580(00)00183-4  0.446
2000 Cummings JL. New tests for dementia. Neurology. 55: 1601-2. PMID 11113211 DOI: 10.1212/Wnl.55.11.1601  0.392
2000 Chung JA, Cummings JL. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurologic Clinics. 18: 829-46. PMID 11072263 DOI: 10.1016/S0733-8619(05)70228-0  0.39
2000 Cummings JL. Neuroimaging in the dementia assessment: is it necessary? Journal of the American Geriatrics Society. 48: 1345-6. PMID 11037028 DOI: 10.1111/J.1532-5415.2000.Tb02614.X  0.354
2000 Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry. 57: 968-76. PMID 11015815 DOI: 10.1001/Archpsyc.57.10.968  0.37
2000 Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. The Journal of Neuropsychiatry and Clinical Neurosciences. 12: 233-9. PMID 11001602 DOI: 10.1176/Jnp.12.2.233  0.308
2000 Mega MS, Dinov ID, Lee L, O'Connor SM, Masterman DM, Wilen B, Mishkin F, Toga AW, Cummings JL. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 12: 209-18. PMID 11001599 DOI: 10.1176/Jnp.12.2.209  0.392
2000 Chow TW, Ross L, Fox P, Cummings JL, Lin KM. Utilization of Alzheimer's disease community resources by Asian-Americans in California. International Journal of Geriatric Psychiatry. 15: 838-47. PMID 10984731 DOI: 10.1002/1099-1166(200009)15:9<838::Aid-Gps209>3.0.Co;2-U  0.387
2000 Lindau M, Almkvist O, Kushi J, Boone K, Johansson SE, Wahlund LO, Cummings JL, Miller BL. First symptoms--frontotemporal dementia versus Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 11: 286-93. PMID 10940680 DOI: 10.1159/000017251  0.412
2000 Miller BL, Boone K, Cummings JL, Read SL, Mishkin F. Functional correlates of musical and visual ability in frontotemporal dementia. The British Journal of Psychiatry : the Journal of Mental Science. 176: 458-63. PMID 10912222 DOI: 10.1192/Bjp.176.5.458  0.318
2000 Edwards-Lee T, Cook I, Fairbanks L, Leuchter A, Cummings JL. Quantitative electroencephalographic correlates of psychosis in Alzheimer disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 13: 163-70. PMID 10910086  0.333
2000 Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Cerebral correlates of psychotic symptoms in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 69: 167-71. PMID 10896687 DOI: 10.1136/Jnnp.69.2.167  0.4
2000 Hirono N, Mega MS, Dinov ID, Mishkin F, Cummings JL. Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. Archives of Neurology. 57: 861-6. PMID 10867784 DOI: 10.1001/Archneur.57.6.861  0.367
2000 Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 97: 6037-42. PMID 10811879 DOI: 10.1073/Pnas.090106797  0.372
2000 Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 8: 134-40. PMID 10804074 DOI: 10.1097/00019442-200005000-00008  0.383
2000 Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology. 54: 1616-25. PMID 10762503 DOI: 10.1212/Wnl.54.8.1616  0.339
2000 Cummings JL. A window on the role of dopamine in addiction disorders. Journal of Neurology, Neurosurgery, and Psychiatry. 68: 404. PMID 10727473 DOI: 10.1136/Jnnp.68.4.404  0.318
2000 Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, Mintz J. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Archives of General Psychiatry. 57: 47-53. PMID 10632232 DOI: 10.1001/Archpsyc.57.1.47  0.319
2000 Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. The American Journal of Psychiatry. 157: 4-15. PMID 10618007 DOI: 10.1176/Ajp.157.1.4  0.342
2000 Leon J, Neumann PJ, Hermann RC, Hsu M, Cummings JL, Doraiswamy PM, Marin D. Health-related quality-of-life and service utilization in Alzheimer's disease: A cross-sectional study American Journal of Alzheimer's Disease. 15: 94-108. DOI: 10.1177/153331750001500206  0.377
2000 Thompson P, Mega M, Woods R, Zoumalan C, Lindshield C, Blanton R, Moussai J, Holmes C, Dinov I, Cummings J, Toga A. Early cortical change in Alzheimer's disease detected using cortical pattern matching and a disease-specific population-based brain atlas Neuroimage. 11: S147. DOI: 10.1016/S1053-8119(00)91080-2  0.357
2000 Cummings JL. Update of pharmacologic management of behavioral disturbances in Alzheimer's disease Neurobiology of Aging. 21: 8. DOI: 10.1016/S0197-4580(00)82710-4  0.371
2000 Cummings JL. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia Current Psychiatry Reports. 2: 419-419. DOI: 10.1007/S11920-000-0025-3  0.315
1999 Ringman JM, Cummings JL. Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. Expert Opinion On Investigational Drugs. 8: 463-71. PMID 15992092 DOI: 10.1517/13543784.8.4.463  0.45
1999 McPherson S, Back C, Buckwalter JG, Cummings JL. Gender-related cognitive deficits in Alzheimer's disease. International Psychogeriatrics / Ipa. 11: 117-22. PMID 11475426 DOI: 10.1017/S1041610299005670  0.391
1999 Cummings JL, Fairbanks L, Masterman DL. Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 2: 59-66. PMID 11281971 DOI: 10.1017/S1461145799001340  0.434
1999 Hirono N, Cummings JL. Neuropsychiatric aspects of dementia with Lewy bodies. Current Psychiatry Reports. 1: 85-92. PMID 11122909 DOI: 10.1007/S11920-999-0014-0  0.336
1999 Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski VC. The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Disease and Associated Disorders. 13: S21-9. PMID 10609678 DOI: 10.1097/00002093-199912001-00005  0.43
1999 Ringman JM, Cummings JL. Metrifonate: update on a new antidementia agent. The Journal of Clinical Psychiatry. 60: 776-82. PMID 10584768 DOI: 10.4088/Jcp.V60N1111  0.427
1999 Mendez MF, Ottowitz W, Brown CV, Cummings JL, Perryman KM, Mandelkern MA. Dementia with leukoaraiosis: clinical differentiation by temporoparietal hypometabolism on (18)FDG-PET imaging. Dementia and Geriatric Cognitive Disorders. 10: 518-25. PMID 10559569 DOI: 10.1159/000017199  0.419
Hide low-probability matches.